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COMPOSITIONS, METHODS AND DEVICES 
FOR GENERATING NANOTUBES ON A 
SURFACE
CROSS-REFERENCE TO RELATED 
APPLICATIONS
This application is a continuation-in-part of PCT/US2011/ 
051578, filed Sep. 14, 2011, which claims the benefit of U.S. 
Provisional Application 61/382,761, filed Sep. 14, 2010, and 
is a continuation-in-part of PCT/US2012/055163, filed Sep. 
14,2012, which claims the benefit of U.S. Provisional Appli­
cation No. 61/534,739, filed Sep. 14,2011; each of the above- 
mentioned applications is incorporated by reference herein in 
its entirety.
FIELD OF THE INVENTION
The present invention relates to methods and apparatus for 
generating nanotubes on a surface.
BACKGROUND OF THE INVENTION
Due to their biocompatibility, titanium and titanium alloys 
are used in a variety of biomedical devices, including ortho­
pedic and dental implants. Titanium and titanium alloys are 
ideally suited to such applications because they are not only 
corrosion resistant, but also have the ability to be integrated 
into bone. Titanium can be subjected to surface modification 
to alter its biocompatibility, for example by electrochemical 
etching. Electrochemical etching generates nanotubes of tita­
nium oxide. Electrochemical etching and other modifications 
can be used to modulate the hydrophobicity/hydrophilicity of 
the surface. Enhancing hydrophobicity results in a surface 
that is not easily wettable and sheds water. Enhancing hydro- 
philicity results in a surface that is wettable and supports cell 
growth. For example, titania nano tubes can be produced by 
etching titanium foil in an aqueous electrolyte containing 
fluoride ions. Conventional methods use a two-electrode DC 
anodization process that is carried out in a vessel containing 
an aqueous electrolyte containing fluoride ions, such as 
hydrofluoric acid, with the titanium foil acting as the working 
anode, and a platinum mesh acting as the cathode. Conven­
tional methods have proved unsatisfactory because they typi­
cally require the use of expensive metals, such as platinum, 
and/or hazardous chemicals, such as hydrofluoric acid, as a 
fluoride ion source. Moreover, their commercial applicability 
is limited because they are most suitable for the uniform 
modification of small flat titanium foils. Improved methods 
for modifying surfaces having complex geometries are 
urgently required for use in orthopedic and dental applica­
tions. Advantageously, such methods would provide for the 
selective modification of portions of the surface using non- 
hazardous electrolytes and inexpensive electrodes.
SUMMARY OF THE INVENTION
As described below, the present invention features compo­
sitions, devices, and methods for generating nanotubes on a 
surface (e.g., a titanium or titanium alloy surface) and for 
incorporating an antimicrobial agent into the nanotubes in a 
controlled manner.
The invention provides for the modification of a surface to 
generate nanotubes at selected sites on the surface using one 
or more point or cylindrical graphite electrodes. In one 
embodiment, the methods of the invention feature the use of 
non-hazardous electrolytes. Compositions and articles
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defined by the invention were isolated or otherwise manufac­
tured in connection with the examples provided below. Other 
features and advantages of the invention will be apparent 
from the detailed description, and from the claims.
In one embodiment the invention provides a method for 
modifying a surface by generating nanotubes at one or more 
selected sites on the surface, the surface including a first 
metal. The method includes the steps of positioning at least 
one cathode and at least one anode relative to the surface in an 
electrolyte solution including a fluoride salt of a second 
metal; and applying a voltage between the at least one anode 
and the at least one cathode sufficient to generate nano tubes at 
one or more selected sites on the surface and to inhibit nano­
tube formation at one or more of the other selected sites, 
wherein the nanotubes include the first metal and the second 
metal.
The invention also provides a titanium or titanium alloy 
surface modified according to the disclosed methods, and a 
biomedical implant or device having a surface, at least a 
portion of which is modified according to the disclosed meth­
ods.
The invention further provides a method for modifying a 
surface by generating nanotubes at one or more selected sites 
on the surface, the surface including titanium. The method 
includes the steps of positioning at least one cathode and at 
least one anode relative to the surface in an electrolyte solu­
tion including silver; and applying a voltage between the at 
least one anode and the at least one cathode sufficient to 
generate nanotubes at one or more selected sites on the sur­
face and to inhibit nanotube formation at one or more of the 
other selected sites, wherein the nanotubes include titanium 
and silver.
In one aspect, the invention provides a method for modi­
fying a metal surface to generate nanotubes at one or more 
selected sites on the surface, the method involving position­
ing at least one cathode and one or more anodes relative to a 
metal surface in an electrolyte solution, where the anodes are 
in proximity to the metal surface; and applying a voltage 
between the one or more anodes and the cathodes sufficient to 
generate nano tubes at one or more selected sites and to inhibit 
nanotube formation at other selected sites.
In another aspect, the invention provides a method for 
modifying a metal surface at one or more selected sites on the 
surface, the method involving positioning one or more anodes 
in proximity to a metal surface in an electrolyte solution; and 
applying a voltage between the one or more anodes and one or 
more cathodes sufficient to modify the metal surface at one or 
more selected sites and to inhibit modification at other 
selected sites.
In an additional aspect, the invention provides a method for 
modifying a metal surface to generate nanotubes at one or 
more selected sites on the surface, the method involving posi­
tioning at least one cathode and an anode array having a 
plurality of anodes in an electrolyte solution, where the 
anodes are in proximity to the metal surface; and applying a 
voltage between the cathode and the anode array sufficient to 
generate nano tubes at one or more selected sites and to inhibit 
nanotube formation at other selected sites.
In still another aspect, the invention provides a device for 
modifying a titanium or titanium alloy surface to form nano­
tubes at one or more selected sites on the surface, having at 
least one cathode, one or more anodes and a titanium or 
titanium alloy surface in an electrolyte solution, where the 
one or more anodes is in proximity to the surface; at least one 
power supply in electrical communication with the cathode 
(s) and anode(s), where nanotubes are formed on the surface 
when voltage is applied in the presence of an electrolyte
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solution; and a support for positioning the cathode and one or 
more anodes relative to the surface. In various embodiments, 
the device has two or more point or cylindrical cathodes or 
anodes positioned relative to selected sites on the surface.
In various embodiments of any of the aspects delineated 
herein, the modification of the metal surface involves nano­
tubes or the generation of nanotubes. In various embodiments 
of any of the aspects delineated herein, the surface is polished 
and/or sequentially sonicated prior to anodization. In various 
embodiments of any of the aspects delineated herein, the 
surface is titanium or a titanium alloy. In various embodi­
ments, the nano tubes are T102 nano tubes. In particular 
embodiments, the T102 nanotubes have no detectable traces 
of other elements. In various embodiments of any of the 
aspects delineated herein, the nanotubes formed at one 
selected site are the same or different in length and diameter 
from nanotubes formed at another site on the surface. In 
various embodiments of any of the aspects delineated herein, 
the surface is present on a biomedical implant or medical 
device. In particular embodiments, the implant is a dental 
implant, cardiovascular implant, neurological implant, neu­
rovascular implant, gastrointestinal implant, muscular 
implant, orthopedic implant, cochlear implant, and/or ocular 
implant. In specific embodiments, the orthopedic implant is a 
joint implant, spinal implant, screw, pin, rod, and/or plate. In 
various embodiments of any of the aspects delineated herein, 
the method involves loading the nanotubes with an effective 
amount of a biologically active agent. In various embodi­
ments of any of the aspects delineated herein, the nanotubes 
contain or have an effective amount of an agent. In various 
embodiments, the agent is an antimicrobial, anti-inflamma­
tory, growth factor, or statin.
In various embodiments of any of the aspects delineated 
herein, the electrolyte solution contains NH4F. In various 
embodiments the electrolyte solution contains ethylene gly­
col or propylene glycol. In various embodiments of any of the 
aspects delineated herein, the anodes and cathode are graph­
ite. In various embodiments of any of the aspects delineated 
herein, the cathode or anodes are point or cylindrical elec­
trodes. In various embodiments of any of the aspects delin­
eated herein, the applied voltage is +60 VDC. In various 
embodiments of any of the aspects delineated herein, the 
anode is positioned between 0.01-10 mm from the surface. In 
various embodiments of any of the aspects delineated herein, 
the cathode is positioned between 1-100 mm from the sur­
face. In various embodiments of any of the aspects delineated 
herein, the voltage, time for which the voltage is applied, and 
distance between the anodes and the surface is varied.
In various embodiments of any of the aspects delineated 
herein, surface modification is inhibited on a portion of the 
metal surface in proximity to at least one of the anodes or 
array of anodes. In various embodiments of any of the aspects 
delineated herein, nanotube growth is reduced or absent at 
one or more selected sites on the surface. In various embodi­
ments of any of the aspects delineated herein, the distance of 
the cathode and/or anode relative to the surface, voltage, and 
time for which the voltage is applied are selected to form 
nano tubes whose length and/or diameter differs between sites 
on the surface.
In various embodiments of any of the aspects delineated 
herein, the surface is thermally treated following modifica­
tion. In particular embodiments, the thermal treatment is car­
ried out between 300 and 500 [deg.JC. In various embodi­
ments of any of the aspects delineated herein, the method 
increases the wettability of the surface. In various embodi­
ments of any of the aspects delineated herein, the method 
enhances the ability of the surface to support cell growth. In
3
various embodiments of any of the aspects delineated herein, 
the nanotubes contain a cell. In particular embodiments, the 
cell is an osteoblast, fibroblast, or a progenitor or a descendant 
of the cell.
DEFINITIONS
By “agent” is meant any small compound, antibody, 
nucleic acid molecule, or polypeptide, or fragments thereof.
By “antimicrobial” is meant an agent that inhibits or sta­
bilizes the proliferation or survival of a microbe. In one 
embodiment, a bacteriostatic agent is an antimicrobial. In 
other embodiments, any agent that kills a microbe (e.g., bac­
terium, fungus, virus) is an antimicrobial.
By “anti-inflammatory” is meant an agent that reduces the 
severity or symptoms of an inflammatory reaction in a tissue. 
An inflammatory reaction within tissue is generally charac­
terized by leukocyte infiltration, edema, redness, pain, and/or 
neovascularization. Inflammation can also be measured by 
analyzing levels of cytokines or any other inflammatory 
marker.
By “biomedical implant” is meant any exogenous material 
that is introduced in to the body of a subject.
By “descendant” is meant a cell type that arises from the 
cell division and/or differentiation of a progenitor cell.
By “effective amount” is meant the amount of an agent 
required to ameliorate the symptoms of a disease relative to 
an untreated patient. The effective amount of active agent(s) 
used to practice the present invention for therapeutic treat­
ment of a disease varies depending upon the manner of 
administration, the age, body weight, and general health of 
the subject. Ultimately, the attending physician or veterinar­
ian will decide the appropriate amount and dosage regimen. 
Such amount is referred to as an “effective” amount.
By “elution rate” is meant the time required for an agent to 
be substantially released from a composition. Elution can be 
measured by determining how much of an agent remains 
within the composition or by measuring how much of an 
agent has been released into the composition’s surroundings. 
Elution may be partial (10%, 25%, 50%, 75%, 80%, 85%, 
90%, 95% or more) or complete. In one preferred embodi­
ment, the agent continues to be released at an effective level 
for at least about 3, 4, 5, 6, 7, 8, 9, or 10 days.
By “infection” is meant the presence of one or more patho­
gens in a tissue or organ of a host. An infection includes the 
proliferation of a microbe (e.g., bacteria, viruses, fungi) 
within a tissue of a subject at a site of trauma.
By “progenitor” is meant a cell that gives rise during divi­
sion and/or differentiation to another cell type.
By “proximity” is meant a distance sufficient for an anode 
to inhibit nanotube formation at a desired site. In one embodi­
ment, an anode is in proximity to a site when it is about 1 -20 
mm from the site.
By “reference” is meant a standard or control condition.
By “selected site” is meant a portion of the surface that is 
chosen for modification. In contrast, other portions of the 
surface—sites that are not selected—are not modified.
By “subject” is meant a mammal, including, but not limited 
to, a human or non-human mammal, such as a bovine, equine, 
canine, ovine, or feline.
Ranges provided herein are understood to be shorthand for 
all of the values within the range. For example, a range of 1 to 
50 is understood to include any number, combination of num­
bers, or sub-range from the group consisting 1, 2, 3,4, 5, 6, 7, 
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 
25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41, 
42, 43, 44, 45, 46, 47, 48, 49, or 50.
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Unless specifically stated or obvious from context, as used 
herein, the term “or” is understood to be inclusive. Unless 
specifically stated or obvious from context, as used herein, the 
terms “a”, “an”, and “the” are understood to be singular or 
plural.
Unless specifically stated or obvious from context, as used 
herein, the term “about” is understood as within a range of 
normal tolerance in the art, for example within 2 standard 
deviations of the mean. About can be understood as within 
10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 
0.05%, or 0.01% of the stated value. Unless otherwise clear 
from context, all numerical values provided herein are modi­
fied by the term about.
Any compositions or methods provided herein can be com­
bined with one or more of any of the other compositions and 
methods provided herein.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic of a nanotube etching system. The 
cathode electrode shown here is graphite, which was used as 
a replacement for platinum (which is more cost-prohibitive). 
The same set up was used during etching experiments using 
platinum (Pt), copper (Cu), stainless steel, and graphite as 
counter electrodes.
FIG. 2 shows SEM images of nanotubes etched with dif­
ferent counter electrodes and their corresponding EDS analy­
sis: Pt electrode (FIG. 2A), Stainless steel electrode (FIG. 
2B), Cu electrode (FIG. 2C), and Graphite electrode (FIG. 
2D).
FIG. 3 is a schematic diagram showing a basic electro­
chemical nanotube fabrication apparatus.
FIGS. 4 A and 4B are images showing nano tubes etched 
with graphite electrodes produced according to methods of 
the invention. Nanotubes etched with graphite cylindrical 
electrode (FIG. 4A) were longer than nanotubes etched with 
graphite point electrode (FIG. 4B). Nano tubes etched with a 
graphite point electrode have a length useful for orthopedic 
applications.
FIGS. 5A and 5B show that varying diameters of T i02 
nanotubes can be produced using methods of the invention. 
FIG. 5A shows SEM images of T i02 nanotubes of varying 
diameters. FIG. 5B shows a graph of T i02 nanotube diameter 
v. time at 20V, 40V, and 60V.
FIGS. 6A and 6B depict transmission electron microscopy 
(TEM) images of T i02 nanotube surfaces (TNT) structured 
surfaces. As-synthesized nanotubes are amorphous (FIG. 
6A), and annealed nanotubes are crystalline (FIG. 6B).
FIGS. 7A and 7B depict the wettability of T i02 nano tube 
surfaces. Representative image comparison of the initial con­
tact angles. FIG. 7A shows six samples in total that were 
investigated, including pure titanium and titanium alloys hav­
ing bare surfaces, not-annealed TNT surfaces, and annealed 
TNT surfaces. FIG. 7B shows a plot of results of the contact 
angles on the surfaces. The TNT surfaces were more hydro­
philic and the annealing effect made the TNT surface super- 
hydrophilic. Contact angle differences were attributed to the 
surface properties, in particular the surface roughness, which 
could affect the initial contact angle of a water droplet on each 
titanium surface.
FIG. 8 shows a comparison of the time-dependent change 
of surface wettability of T i02 nanotube surfaces. Annealed 
TNT (Pt/alloy), As-grown TNT (Pt/alloy), and bare foil (al­
loy) were compared. As time passed, the TNT surface hydro- 
phobicity increased.
FIGS. 9 A and 9B depict the comparison of the time-depen- 
dent contact angles. FIG. 9A shows water droplet wettability
5
on annealed and as-anodized TNT surfaces. The increasing 
contact angles varied in each case but all of the TNT samples 
increased the surface wettability. FIG. 9B shows the cases of 
bare titanium. In these cases, the wettability had little, if any, 
change with time.
FIG. 10 is a top view schematic of a basic single graphite 
cylinder electrode system to inhibit nano tube growth near the 
+60 VDC electrode (marked +), where the titanium substrate 
is placed between the electrodes.
FIG. 11 depicts images of the two sides of a titanium 
specimen etched using a single graphite cylinder electrode to 
inhibit nanotube growth near the +60 VDC electrode as 
shown in FIG. 10.
FIG. 12 is a top view schematic of a single graphite cylin­
der electrode system to inhibit nanotube growth near the +60 
VDC electrode (marked +), where the +60 VDC electrode is 
placed between the titanium and the graphite rod electrode.
FIG. 13 depicts images of the two sides of a titanium 
specimen etched using a single graphite cylinder electrode to 
inhibit nanotube growth near the +60 VDC electrode as 
shown in FIG. 12.
FIG. 14 is a top view schematic of a system to inhibit 
nanotube growth in one-half of a titanium specimen in which 
nanotube growth is inhibited using a graphite cylindrical rod 
electrode (marked +), where the electrodes are placed in close 
proximity to each other and the titanium substrate.
FIG. 15 depicts images of the two sides of titanium speci­
men etched using a single graphite cylinder electrode to 
inhibit nanotube growth near +60 VDC electrode in FIG. 14.
FIG. 16 is a schematic of an automated and reconfigurable 
nanotube etching system. Each point or rod electrode (1, 2,3, 
4 , . . . ,  n) is supplied with an etching voltage (Vn), an etching 
time (Tn), and a standoff distance (Dn) for specific nanotube 
dimensions and mechanical stiffness.
FIG. 17 is a graph showing density of adhered MC3T3 cells 
as a function of incubation time on the surface of commer­
cially pure (cp) Ti (left) and alloy Ti (right) with different 
structures. The data confirms the effect of anodization and 
annealing in enhancing cell density in comparison to control 
bare surfaces for both cp and alloyed substrates. In the cell 
density of annealed substrates there was a slight increase in 
the case of cp nanotubes compared to alloyed nanotubes 
which was due to slightly higher biocompatibility of cp Ti.
FIG. 18 is a graph depicting the effect of nanotube length, 
crystallinity, and composition on cell number and attachment.
FIGS. 19A and 19B are images of FIB milled fibroblast 
cells obtained from a primary ion beam. Internal structures, 
membranes and morphological stability and integrity can be 
assessed; moreover, the interface between the cell and the 
substrate can be observed. Scale bars are 5 pm (FIG. 19A), 
and 10 pm (FIG. 19B).
FIGS. 20A-20D show SEM images of a cross-sectional 
view of the cell-nanotube interface (FIGS. 20A and 20B), 
milled by the FIB technique and a magnified view of cell- 
nanotube interaction and filopodia growth inside a nanotube 
(FIGS. 20C and 20D). Scale bars are 2 pm (FIG. 20A), 1 pm 
(FIG. 20B), and 500 nm (FIGS. 20C and 20D).
FIGS. 21A-21G are images showing osteoblast cell inter­
action with T i02 nanotubes. The extension of osteoblast cells 
for adhesion on the nanotubes as well as cell clusters on the 
nanotube surface (FIGS. 21A-21C) indicate the ability of the 
nanotube structure to promote cell adhesion and growth. 
Scale bars are 100 pm (FIG. 21A), 50 pm (FIG. 21B), and 10 
pm (FIG. 21C). FIGS. 21D-21F are images showing cell 
filopodia attachment and spreading on and between nano­
tubes. The nano tubes can act as anchors for cell filopodia to 
grab (FIG. 21F) and increase the spreading (FIG. 21D) and
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improve its attachment (FIG. 21E). Scale bars are 3 pm (FIG. 
21D), 500 mn (FIG. 21E), and 1 pm (FIG. 21F). FIG. 21G is 
an image showing an osteoblast filopodia—its foot used for 
locomotion—anchored to titanium nanotubes and ECM pro­
duction on and in between nanotubes during cell migration 
and bone matrix deposition. Scale is 50 pm.
FIG. 22A-22F are images of FIB cross sectional milling 
revealing titania nanotubes which have been clogged by 
osteoblast and calcium deposition on nanotubes as a result of 
cell attachment and direct contact with surface. Scale bars are 
200 pm (FIG. 22A), 50 pm (FIG. 22B), 20 pm (FIG. 22C), 5 
pm (FIGS. 22D and 22F), and 10 pm (FIG. 22E).
FIG. 23 depicts EDS analysis of clogged nanotubes as 
shown in a high-resolution scanning electron micrograph (in­
set). The clogged nanotubes were visible and composed of Ca 
and P (by EDS), the primary components of bone matrix. 
Scale bar is 1 pm.
FIGS. 24A and 24B are scanning electron micrograph 
images of nanotube-covered Ti6A14V ELI cancellous bone 
screws. Scale bars are 1 mm (FIG. 24A) and 1 pm (FIG. 24B).
FIG. 25 is a graph showing the comparison of insertion 
torque and pilot-hole diameter for a bare Ti6A14V ELI can­
cellous bone screw.
FIG. 26 is a graph showing a comparison of insertion 
torque for a bare Ti6A14V ELI cancellous bone screw and a 
nanotube-covered Ti6A14V ELI cancellous bone screw.
FIG. 27 is an SEM image of a nanotube-covered bone 
screw after insertion and removal in a 5 mm pilot hole in bone 
stimulant and subsequent insertion and removal in a 3.2 mm 
pilot hole in bone stimulant.
FIG. 28 is an SEM image of a nanotube-covered bone 
screw after insertion and removal in a 5 mm pilot hole in bone 
stimulant and subsequent insertion and removal in 3.2 mm 
pilot hole in bone stimulant, and after cleaning by vaporiza­
tion of bone stimulant and sonication cleaning.
FIG. 29 is a graph depicting typical etching current (mA) 
vs. time (minutes) for nanotube formation in Ti6A14V at: 60 
VDC (top-most curve); 40 VDC (middle curve); and 20 VDC 
(bottom-most curve). Mathematical curve fitting shows good 
correlation with a natural logarithmic behavior. Because 
nanotube morphology is also correlated with etching time, 
etching current can be used as a feedback parameter in an 
automated production system.
FIGS. 30A and 30B are scanning electron micrograph 
images of nanotubes on titanium alloy Ti6A14V fabricated 
with AgF-containing electrolyte. Etching conditions were 60 
VDC and time of 30 minutes. Nanotube length was approxi­
mately 2 microns. Only trace levels of silverwere found when 
conducting elemental analysis. Scale bars are 1 pm (FIG. 1A), 
and 500 nm (FIG. IB).
FIG. 31 is a scanning electron micrograph image of nano ­
tubes on titanium alloy Ti6A14V fabricated with AgF-con- 
taining electrolyte. Etching conditions were 60 VDC and time 
of 30 minutes. Electrode polarity was immediately reversed 
and silver deposition time was 15 minutes.
FIG. 32 shows the relative presence of silver associated 
with a nanotube surface, on both an atomic percent presence 
and a weight percent presence as measured by eneigy-disper- 
sive X-ray spectroscopy.
DETAILED DESCRIPTION OF THE INVENTION
The present invention generally features compositions and 
methods for generating nanotubes on a surface (e.g., a tita­
nium or titanium alloy surface) at selected sites and coating 
the nanotubes with a second metal or incorporating the sec­
ond metal into the nanotubes, either as a separate step or in
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conjunction with nanotube formation. In one embodiment, 
the secondmetal (e.g., calcium) enhances the surface’s ability 
to support mammalian cell growth. In another embodiment, 
the second metal (e.g., silver) has anti-microbial activity that 
reduces the propensity of the surface to support microbial 
(e.g., bacterial, fungal) growth. In yet another embodiment, a 
combination of two or more fluoride salts in the electrolyte 
(such as, but not limited to, silver fluoride and calcium fluo­
ride) will result in the combined properties. In various 
embodiments, the invention includes methods for adjusting 
the amount of the second metal that is added to the nanotubes 
in order to control the properties that the second metal pro­
duces.
The invention is based, at least in part, on the following 
discoveries: first, that nanotubular structures can be fabri­
cated using a benign electrolyte comprising ethylene glycol, 
water, and ammonium fluoride, silver fluoride and/or calcium 
fluoride; nanotubular structures are fabricated using inexpen­
sive graphite rod or graphite point electrodes, rather than 
expensive platinum electrodes; third, graphite point elec­
trodes can be used to selectively fabricate nanotubes at 
desired sites, while concurrently inhibiting generation of 
nano tubes at other sites; and finally, that by varying the volt­
age applied at each of the electrodes and varying the length of 
time the voltage is applied the surface can be selectively 
modified at discrete sites with nanotubular structures of 
selected lengths. Advantageously, these nanotubes can be 
further modified to comprise a second metal. In particular 
embodiments, the invention features arrays of electrodes suit­
able for selectively modifying surfaces having complex 
geometries, such that the growth of nanotubes is permitted at 
particular sites and concurrently inhibited at other sites. As 
reported in more detail below, nanotubular structures are fab­
ricated into Ti6A14V ELI surgical orthopedic cancellous and 
cortical bone screws using electrodes of the invention. These 
nano tubes survive multiple insertion and removal cycles in an 
accepted bone simulant material. Accordingly, the invention 
provides benign electrolytes, electrodes (e.g., graphite point 
and cylindrical electrodes), and automated devices compris­
ing point and/or cylindrical electrodes for fabricating nano­
tubes on the surface of pure and Ti6A14V titanium sheets and 
Ti6A14V ELI orthopedic hardware by anodization. In certain 
embodiments, this process advantageously modifies the sur­
face to enhance mammalian cell growth and adhesion and/or 
to reduce the surface’s ability to support microbial cell 
growth.
Electrolyte
The present invention utilizes electrolytes suitable for use 
in the electrochemical etching or modification of surfaces 
(e.g., titanium and titanium alloys) to generate nanotubular 
structures. The electrolytes used in the invention are advan­
tageously free of hydrofluoric acid and other caustic, hazard­
ous, or otherwise dangerous sources of fluoride ions. Because 
these electrolytes are benign they are suitable for modifica­
tion of surfaces to be implanted in a subject to enhance cell 
growth and cell adhesion. In particular, the invention utilizes 
aqueous electrolytes comprising ethylene glycol or propylene 
glycol, water, and a fluoride-containing salt. The fluoride- 
containing salt is in solution (i.e., in water). The amount of 
water in the electrolyte is about 0.1%, 0.25%, 0.5%, 1-2%, 
5%, or 10% (v/v). The fluoride-containing salt may include 
one or a combination of fluoride-containing salts (e.g., 
ammonium fluoride, silver fluoride and/or calcium fluoride). 
In a particular embodiment, the fluoride-containing salt is 
ammonium fluoride. The amount of fluorine atom present in 
the electrolyte can be determined or calculated using methods 
known in the art. For example, fluorine is about 51% of
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ammonium fluoride by weight. The electrolyte contains about 
5-1000 mg fluorine/100 ml (e.g, 5,10, 25, 50, 100, 200, 250, 
300, 400, 500, 750, 1000 mg fluorine/ml). In a particular 
embodiment, the electrolyte comprises up to 330 mg fluoride 
ion/50 ml electrolyte. It has been observed that increasing the 
amount of fluoride ion in the electrolyte decreases etch times, 
and weaker electrolyte etches more slowly. Etch times range 
from 5 minutes-60 minutes (e.g., 5, 10, 15,20,25,30,35,40, 
45, 50, 55, 60 minutes). In a specific embodiment, 337 mg 
fluorine/100 ml provides a desirable etch time.
Electrodes and Electrode Geometry
Conventional anodization methods use a two-electrode DC 
anodization process that is carried out in a vessel containing 
an aqueous electrolyte containing fluoride ions, such as 
hydrofluoric acid. In this conventional system, titanium foil 
acts as the anode and a platinum mesh acts as the cathode. The 
use of a platinum cathode increases the cost associated with 
anodization. The invention advantageously provides electro­
chemical etching methods featuring graphite point and cylin­
drical electrodes (e.g., cathodes, anodes), which provide a 
significant cost savings.
The invention further provides for the use of one or more 
inhibitory electrodes (e.g., anodes) to which voltage (e.g., 
+60 VDC) is applied. The inhibitory electrode selectively 
inhibits nanotube fabrication at selected sites on the surface. 
This is particularly useful for biomedical implants where cell 
growth can be enhanced at desired portions of the implant 
surface and inhibited at other sites on the implant surface. In 
one embodiment, the formation/inhibition of nanotubes and 
the deposition of a second metal is carried out in a single 
electrolyte. In another embodiment, the formation/inhibition 
of nanotubes is carried out in a first electrolyte (e.g., ammo­
nium fluoride) and the deposition of a second metal is carried 
out in a second electrolyte (e.g., silver fluoride, calcium fluo­
ride).
The invention further features the use of electrode arrays 
(e.g., two, three, four, five, six, seven, eight, nine, ten, ormore 
electrodes) that are positioned in three-dimensional space 
relative to the titanium surface to be modified. This provides 
for the growth of nanotubes on surfaces having complex 
geometries. In particular embodiments, one or more of the 
electrodes is positioned in the electrolyte together with the 
surface to be modified. Between +25 and 100 VDC is applied 
to one or more of the electrodes. Other electrodes serve as 
ground electrodes. In one embodiment, 50, 55, 60, 65, or 70, 
110, 120, 150, 175,200VDC or up to the electrolyte break­
down voltage is applied to one or more electrodes. The area of 
inhibition of nano tube formation may be controlled by adjust­
ing the number and/or proximity of inhibitory anodes. Large 
areas of the surface may be inhibited for nanotube formation 
by using multiple inhibitory electrodes without limitation 
(e.g., over a square foot). Depending on the size of the elec­
trode, nanotube formation may be inhibited over smaller 
areas (e.g., using a point electrode). It has been observed that 
the area of inhibition of nanotube formation is approximately 
the diameter of point electrode plus 2x the gap distance (e.g., 
a 1 mm point electrode, 1 mm from surface, yields a zone of 
inhibition about 3 mm). Areas where inhibition is inhibited 
can be from less than 1 mm2to ameter2 ormore (e.g., 0.1,0.5, 
1 ,2 ,3 ,4 ,5 ,10,25, 50,100,125,150,175,200,300,400, 500, 
600, 700, 800, 900, 1000 mm). Additionally, the closer the 
anode is to the substrate, the smaller the area of inhibited tube 
growth. The ability to modify the formation of nanotubes is 
advantageous for modulating cellular interactions with the 
surface, e.g., to promote preferential cell growth, encourage 
osteoblast growth and/or migration, to prevent fibroblast 
growth and/ormigration, orto prevent angiogenesis in a stent.
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If desired, an inhibitory electrode may be fabricated of carbon 
nanotubes and used to inhibit nanotube formation on a sur­
face. Such inhibitory electrodes may be 0.5, 1 mm, 2 mm, or 
3 mm in diameter. In general, a point electrode or cylindrical 
electrode(s) is positioned at a distance that is between about 
0.1, 0.05, 1 mm to about 100 mm or more (e.g., 1, 3, 5, 6, 7, 
8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 
85, 90, 95, 100 mm) from the substrate. There should be no 
limit to this separation distance. The smallest distance for 
position depends on the electrical strength of the electrolyte, 
the voltage between the anode and metal substrate, and the 
thickness of electrolyte. The gap should be small enough so as 
not to exceed the breakdown voltage between electrode and 
titanium (i.e., does not arc). Nanotubes are quickly fabricated 
with a voltage up to +60 VDC, although other voltages can be 
used to fabricate nano tubes having the desired properties. 
Such voltage are selected to optimize nanotube length to 
support cell growth and to optimize for mechanical stability. 
The electrodes in an array may have the same voltages applied 
or may have different voltages. They may be at the same 
distance from the surface or at different distances.
In particular embodiments, nanotubes are preferentially 
formed or inhibited by the positioning of one or more point or 
cylindrical electrodes. For example, as shown in FIG. 11, 
nanotube growth is inhibited in a substrate in proximity to the 
+60 VDC electrode (“the inhibitory electrode or anode”). The 
distance between the inhibitory electrode and the substrate is 
between about 3-10 mm (e.g., about 3, 4, 5, 6,7, 8, 9, 10 mm) 
A smaller separation distance provides a more localized inhi­
bition of nanotube etching. The separation distance can be as 
small as desired, providing there is sufficient electrolyte 
between the electrode(s) and the specimen surface. Nanotube 
growth occurs on other portions of the surface that are not in 
proximity to the inhibitory electrode. The distance between 
the cylindrical graphite ground electrode and the substrate is 
between about 50-100 mm (e.g., 50, 60, 70, 80, 90,100). The 
substrate whose surface is to be modified can be between the 
inhibitory electrode and the ground electrode (as shown in 
FIG. 10), or the inhibitory electrode and the ground electrode 
can be on the same side of the surface to be modified (as 
shown in FIGS. 12 and 14).
Point and cylindrical electrodes can be made of virtually 
any conducting material (e.g., platinum, stainless steel, cop­
per and graphite). Preferably, the electrode is any electrically 
conducting material that does not adversely contaminate the 
surface. Small nanotubes may also be generated using nanos­
cale electrodes including carbon nanotubes and titanium 
nano tubes. In one embodiment, an electrode array comprises 
a combination of graphite point electrodes to which current is 
applied and a single ground electrode. In another embodi­
ment, an electrode array comprises one or a combination of 
graphite point electrodes to which current is applied and 
ground electrodes, which are also graphite point electrodes. 
In some embodiments, electrochemical etching may be moni­
tored by color formation, (e.g., when a copper anode is used). 
Additionally, electrochemical etching may be monitored 
optically (e.g., opaqueness of the electrolyte, UV absorption), 
by measuring the formation of titanium in solution, or by 
detecting changes in conductivity.
By selecting the voltage of each electrode and/or the tita­
nium, nano tube fabrication can be allowed in selected regions 
of the titanium and inhibited in other selected regions of the 
titanium. If the time that the voltage is applied is also varied 
at each of the multiple electrodes in an array nanotubular 
structures of varying lengths can be fabricated at desired sites 
on the substrate.
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Cylindrical electrodes are typically uncoated strands of 
conductive material. Rod electrodes may be composed of 
copper, graphite, or other suitable electrically conductive 
material. Point electrodes are formed when a strand of copper, 
graphite, or other suitable electrically conductive material is 
coated with an insulating layer to produce a single electrical 
near-point source. Insulating layers include, but are not lim­
ited to, plastic heat-shrink tubing, paints, lacquers, epoxies or 
other electrically insulating materials compatible with the 
electrolyte and the process. By using point and cylindrical 
electrodes at the proper locations, distances, voltages, and 
times, tubular nanostructures can also be etched on the sur­
face of interior features, such as holes and sharp depressions 
of regular and irregular shape, interior sharp corners and 
concave features, exterior features such as protrusions of 
regular and irregular shape, exterior sharp comers and convex 
features. Such complex geometries are typically found on the 
surface of orthopedic implants or other implantable devices 
where such tubular nanostructures are desired.
Nanotube Parameters
In general, the length of a nanotube is a function of the 
conditions under which the nano tube was formed. Nano tubu­
lar structures are fabricated on the specimen when the voltage 
potential of the specimen is higher than surrounding elec­
trodes. This is defined as “current leaving” the specimen— 
that is charge is moving from a more positive voltage to a 
lower voltage at any location on the titanium specimen. If 
however, “current enters” the titanium specimen at any loca­
tion, nanotube fabrication is inhibited. Under these specified 
fabrication conditions, the specimen may or may not be elec­
trically connected to the electrochemical etching circuitry. 
The specimen may be allowed to electrically “float” without 
imposing a particular voltage.
The point electrodes and cylindrical electrodes of the 
invention, alone or in arrays, provide for the fabrication of 
arrays of nanotubes. By altering the position of the multiple 
electrodes relative to the surface, the distances of each of the 
electrodes from the surface, the voltage applied to each of the 
multiple electrodes, and the length of time of etching, the 
properties of the nanotubes can be predictably altered (i.e., 
the length, diameter, pore size).
For example, nanotubes are fabricated to have a wall thick­
ness ranging from about 3 nm to about 300 nm (e.g., 3, 5, 10, 
15,20,25,50,75,100,125,150,175,200,225,250,300 nm), 
preferably 5-10 nm. Nanotubes are fabricated to have an inner 
diameter ranging from about 3 nmto about 300 nm (e.g., 3, 5, 
10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 300 
nm), preferably 30-80 nm. Nanotubes are fabricated to have 
an outer diameter ranging from about 3 nm to about 300 nm 
(e.g., 3, 5,10,15,20,25, 50,75,100,125,150,175,200,225, 
250, 300 nm), preferably 80-120 nm. In some embodiments, 
the nanotubes are fabricated at a density of at least about 
100,000,000, 200,000,000, or 300,000,000 nanotubes per 
square centimeter. Exemplary morphologies of titanium 
nanotubes and titanium nanotube surfaces include honey 
comb (see, e.g., FIG. 2A) and free-standing nanotubes (see 
e.g., FIG. 5A). In other embodiments, the nanotubes are fab­
ricated at a density of at least about 25,000,000, 50,000,000, 
or 75,000,000 nanotubes per square centimeter (e.g., free­
standing nanotubes). The nano tube density may range from 
many millions per square centimeter to several billion per 
square centimeter for the closely packed honeycomb configu­
ration. Nanotubes are fabricated to have a length ranging from 
about 1 pm to about 100 pm (e.g., 1, 3, 5, 10, 20, 25, 50, 75, 
100). Nanotubes longer than 10 pm are structurally weak and 
separate from the metal substrate. Nano tubes are fabricated to 
have pores that range in diameter from about 3 nm to about
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250 nm (e.g, 3, 5, 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 
200, 225, 250 nm), preferably 10 nm to 100 nm. Advanta­
geously, the electrode arrays of the invention allow the sur­
face to be heterologously modified. For example, longer 
nanotubes can be fabricated at selected sites on the surface, 
while shorter nano tubes are formed at other selected sites, and 
nanotube formation is inhibited at still other sites.
In other embodiments, the polarity of the anode and cath­
ode are reversed such that nanotubes are fabricated over sites 
on the surface where nanotube growth was previously inhib­
ited. This provides one or more regions of relatively long 
nanotubes and one or more regions of shorter nanotubes, 
based on the total time and current flow direction of each 
region.
In still other embodiments, the polarity of the anode and 
cathode are reversed such that a second metal (e.g, silver, 
calcium) is deposited on the surface. The length of time that 
the voltage is applied determines the amount of metal depos­
ited. In one embodiment, the voltage is applied for between 
about 5-60 (e.g, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60) 
minutes.
Pre-Electrochemical Etching Treatments
Prior to carrying electrochemical etching, the substrate can 
be prepared in any of a variety of ways. The surface may be 
modified to be smooth or made abrasive. For example, the 
surface may be wiped with solvent (e.g, acetone), polished 
(e.g, using colloidal S i02), sonicated (e.g, sequentially soni­
cated in acetone, isopropyl alcohol, and methanol). If desired, 
after the pre-treatment the surface is rinsed with deionized 
water, and dried (e.g, dried under N2). Pre-treatment may at 
least depend in part on the characteristics of the base metal 
(e.g, having fine grains or large grains). Alloys are work 
hardened and have high density dislocation networks, thus, 
abrading the surface exposes grains. To remove exposed 
grains, metal alloys may be heat treated, rinsed with acetone, 
washed to remove the acetone, machined, and polished. 
Post-Electrochemical Etching Treatments
Following electrochemical etching and deposition of a sec­
ond metal, the substrate comprising titanium oxide (Ti02) 
nanotubes can be treated to further modify the surface prop­
erties. T i02 occurs in different crystalline structures. In one 
embodiment, the surface is heated between about 400 and 
500° C. (e.g, 400, 425, 450, 500° C.). Temperatures greater 
than 500° C. may also be used. The surface may be heated for 
one, two, three, four, or five hours. In one embodiment, the 
surface is heated using a rapid thermal annealer. A heating/ 
cooling rate o f308° C./min was used, and the substrates were 
annealed in air at 450° C. for 3 hours. This annealing treat­
ment results in phase transformation of T i02 nano tubes from 
amorphous to crystalline anatase. Anatase is one of the three 
mineral forms of titanium dioxide, the other two being broo- 
kite and rutile. Brookite is orthorhombic, and rutile is the 
most common polymorph. This post-treatment modifies the 
wettability of the surface, alters the surface charge, and may 
alter the structural strength, stiffness, and toughness. For 
example, heat treatment in N2 and/or C 0 2 may be used to 
harden Ti nanotubes or impart other properties.
The invention provides compositions and methods for fab­
ricating nanotubes on the surface of a substrate, such as pure 
and Ti6A14V titanium sheets and Ti6A14V ELI orthopedic 
hardware by electrochemical etching. In certain embodi­
ments, the nano tubes enhance cell growth and adhesion to the 
surface. In one embodiment, such surface modifications 
affect surface wettability and surface potential. Increased 
wettability of a surface means that water will spread out more 
on such a surface. Wettability also is directly related to the 
surface hydrophilicity (i.e, increased hydrophilicity means
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greater wettability) and increased surface energy. Methods 
for measuring wettability are known in the art and described 
in the Examples. In one embodiment, wettability is assayed 
by obtaining contact angles, contact radii, and center-heights 
of water droplets on a nanotube surface. Preferably, the con­
tact angle is reduced following electrochemical etching and/ 
or other post-electrochemical etching treatment relative to the 
contact angle of untreated titanium. In one embodiment, con­
tact angles are decreased by 50-75% compared to the contact 
angles of each bare foil.
Medical Implants and Devices
Surfaces such as titanium or titanium alloy surfaces can be 
modified using the methods described herein to include T i02 
nanotubes comprising a second metal that is deposited onto 
the surface. In certain embodiments, nanotubes are formed on 
titanium and/or titanium alloy implants or devices. In one 
embodiment, the invention provides for the modification of 
the surface of a titanium port (or portacath) for the delivery of 
therapeutics to a subject. Exemplary implants include dental 
implants, cardiovascular implants such as a pacemaker, neu­
rological implants, neurovascular implants, gastrointestinal 
implants, muscular implants, cochlear implants, orthopedic 
implants, and ocular implants where bony fixation or cellular 
attachment is desirably enhanced. Other implants and devices 
include orthopedic devices (e.g., for joint implants, fracture 
repairs, spinal implants, screws, rods, plates); surgical 
devices (e.g., sutures, staples, anastomosis devices, vertebral 
disks, bone pins, suture anchors, hemostatic barriers, clamps, 
screws, plates, clips, vascular implants, tissue adhesives and 
sealants, tissue scaffolds); wound management devices; 
drug-delivering vascular stents (e.g., a balloon-expanded 
stents); other vascular devices (e.g., grafts, catheters, valves, 
artificial hearts, heart assist devices); implantable defibrilla­
tors; blood oxygenator devices (e.g., tubing, membranes); 
membranes; biosensors; shunts for hydrocephalus; endo­
scopic devices; infection control devices; dental devices (e.g., 
dental implants, fracture repair devices), urological devices 
(e.g., penile, sphincter, urethral, bladder and renal devices, 
and catheters); ophthalmic devices (e.g. intraocular coils/ 
screws); glaucoma drain shunts; synthetic prostheses (e.g., 
breast); intraocular lenses; respiratory, peripheral cardiovas­
cular, spinal, neurological, dental, ear/nose/throat (e.g., ear 
drainage tubes); renal devices; and dialysis (e.g., tubing, 
membranes, grafts), urinary catheters, intravenous catheters, 
small diameter grafts, vascular grafts, artificial lung catheters, 
atrial septal defect closures, electro-stimulation leads for car­
diac rhythm management (e.g., pacer leads), glucose sensors 
(long-term and short-term), degradable coronary stents (e.g., 
degradable, non-degradable, peripheral), blood pressure and 
stent graft catheters, birth control devices, prostate cancer 
implants, bone repair/augmentation devices, breast implants, 
cartilage repair devices, dental implants, implanted drug infu­
sion tubes, intravitreal drug delivery devices, nerve regenera­
tion conduits, oncological implants, electrostimulation leads, 
pain management implants, spinal/orthopedic repair devices, 
wound dressings, embolic protection filters, abdominal aortic 
aneurysm grafts, heart valves (e.g., mechanical, polymeric, 
tissue, percutaneous, carbon, sewing cuff), valve annulo- 
plasty devices, mitral valve repair devices, vascular interven­
tion devices, left ventricle assist devices, neuro-aneurysm 
treatment coils, neurological catheters, left atrial appendage 
filters, hemodialysis devices, catheter cuff, anastomotic clo­
sures, vascular access catheters, cardiac sensors, uterine 
bleeding patches, urological catheters/stents/implants, aneu­
rysm exclusion devices, and neuropatches.
Examples of other suitable devices include, but are not 
limited to, vena cava filters, urinary dialators, endoscopic
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surgical tissue extractors, atherectomy catheters, clot extrac­
tion catheters, coronary guidewires, drug infusion catheters, 
esophageal stents, circulatory support systems, angiographic 
catheters, coronary and peripheral guidewires, hemodialysis 
catheters, neurovascular balloon catheters, tympanostomy 
vent tubes, cerebro-spinal fluid shunts, defibrillator leads, 
percutaneous closure devices, drainage tubes, thoracic cavity 
suction drainage catheters, electrophysiology catheters, 
stroke therapy catheters, abscess drainage catheters, biliary 
drainage products, dialysis catheters, central venous access 
catheters, and parental feeding catheters.
Also provided are methods of treating a patient in need of 
a medical implant. The methods involve selecting a medical 
implant where the implant comprises a surface having nano­
tubes capable of enhancing or promoting cell growth or pro­
liferation and placing the implant into the patient. In this 
embodiment, the term “selecting” means, for example, pur­
chasing, choosing, or providing the implant rather than pre­
paring the implant.
By varying the time of electrochemical etching of the 
native material surface, the implant surface can be engineered 
to provide the desired local nano structured surface. By using 
point and cylindrical electrodes at the proper locations, dis­
tances, voltages, and times, tubular nanostructures can also be 
etched on the surface of interior features such as holes and 
sharp depressions of regular and irregular shape, interior 
sharp corners and concave features, exterior features such as 
protrusions of regular and irregular shape, exterior sharp cor­
ners and convex features, all typically found on the surface of 
orthopedic implants or other implantable devices where such 
tubular nanostructures are desired.
Advantageously, second metals or combinations of metals 
are used to coat the surface or are otherwise incorporated into 
the surface to alter its ability to support mammalian cell or 
microbial cell growth.
Nanotubes for Drug Delivery
In another embodiment of the invention, an implant that 
has undergone electrochemical etching is used to deliver 
therapeutic or prophylactic agents in vivo. More specifically, 
the titanium nanotubes on the implant surface act as carriers 
and reservoirs to deliver drugs to certain locations of the body 
over various predetermined time periods.
The invention provides a simple means for delivering bio­
logically active agents (e.g., small compounds, nucleic acid 
molecules, polypeptides) using a nanotube modified implant 
or medical device. The nanotube modified implant is deliv­
ered to a subject and the biologically active agent is eluted 
from the composition in situ.
The agents may be adsorbed onto and incorporated into the 
biodegradable nanostructure surface, by dipping the implant 
into a solution or dispersion containing the agents and/or 
additives, orby othermeans recognized by those skilled in the 
art. In some embodiments, the nanostructure will release the 
adsorbed biological agents and additives in a time-controlled 
fashion. In this way, the therapeutic advantages imparted by 
the addition of biological agents and additives may be con­
tinued for an extended period of time.
The nanotube modified implant is capable of delivering an 
agent for the treatment of a disease or disorder that requires 
controlled and/or localized drug delivery over some period of 
time (e.g., 1, 3, 5, 7 days; 2,3,4 weeks; 1,2,3, 6,12 months). 
Desirably, the nanotube modified implant comprises an effec­
tive amount of one or more antibiotics, growth factors that 
promote cell growth, statins that promote bone growth, small 
molecules, or cartilage or bone repair agents. Preferably, the 
nanotube modified implant comprises at least about 1 pg, 25 
pg, 50 pg, 100 pg, 250 pg, 500 pg, 750 pg, 1 mg, 5 mg, 10 mg,
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25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 250 mg, 300 mg, 400 
mg, or 500 mg of an agent (e.g., an antibiotic). In another 
embodiment, the composition releases at least about 1 pg, 25 
pg, 50 pg, 100 pg, 250 pg, 500 pg, 750 pg, 1 mg, 5 mg, 10 mg, 
25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 250 mg, 300 mg, 400 
mg, or 500 mg of an agent (e.g., an antibiotic) over the course 
of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 21, 28, or 35 
days. In still another embodiment, the composition comprises 
at least about 1 pg, 25 pg, 50 pg, 100 pg, 250 pg, 500 pg, 750 
pg, 1 mg, 5 mg, lOmg, 25 mg, 50mg, 75 mg, 100mg, 200mg, 
250 mg, 300 mg, 400 mg, or 500 mg of an agent (e.g., an 
antibiotic) per cm3.
Anti-Inflammatories
In other embodiments, a nanotube modified implant is used 
to deliver an anti-inflammatory agent. Such anti-inflamma­
tory agents include, but are not limited to, Alclofenac; 
Alclometasone Dipropionate; Algestone Acetonide; Alpha 
Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Ami- 
prilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; 
Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; 
Benzydamine Hydrochloride; Bromelains; Broperamole; 
Budesonide; Carprofen; Cicloprofen; Ciclsporin, Cintazone; 
Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; 
Clopirac; Cloticasone Propionate; Cormethasone Acetate; 
Cortodoxone; Curcumin; Deflazacort; Desonide; Des- 
oximetasone; Dexamethasone Dipropionate; Diclofenac 
Potassium; Diclofenac Sodium; Diflorasone Diacetate; 
Diflumidone Sodium; Diflunisal; Difluprednate; Diftalone; 
Dimethyl Sulfoxide; Drocinonide; Endrysone; Enlimomab; 
Enolicam Sodium; Epirizole; Etodolac; Etofenamate; Felbi- 
nac; Fenamole; Fenbufen; Fenclofenac; Fenclorac; Fendosal; 
Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic 
Acid; Flumizole; Flunisolide Acetate; Flunixin; Flunixin 
Meglumine; Fluocortin Butyl; Fluorometholone Acetate; 
Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propi­
onate; Furaprofen; Furobufen; Halcinonide; Halobetasol Pro­
pionate; Halopredone Acetate; Ibufenac; Ibuprofen; Ibupro- 
fen Aluminum; Ibuprofen Piconol; Ilonidap; Indomethacin; 
Indomethacin Sodium; Indoprofen; Indoxole; Intrazole; Isof- 
lupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemi- 
zole Hydrochloride; Lornoxicam; Loteprednol Etabonate; 
Meclofenamate Sodium; Meclofenamic Acid; Meclorisone 
Dibutyrate; Mefenamic Acid; Mesalamine; Meseclazone; 
Methylprednisolone Suleptanate; Momiflumate; Nabume- 
tone; Naproxen; Naproxen Sodium; Naproxol; Nimazone; 
Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin; 
Oxyphenbutazone; Paranyline Hydrochloride; Pentosan 
Polysulfate Sodium; Phenbutazone Sodium Glycerate; Pir- 
fenidone; Piroxicam; Piroxicam Cinnamate; Piroxicam Ola- 
mine; Pirprofen; Prednazate; Prifelone; Prodolic Acid; Pro- 
quazone; Proxazole; Proxazole Citrate; Rimexolone; 
Romazarit; Salcolex; Salnacedin; Salsalate; Sanguinarium 
Chloride; Seclazone; Sermetacin; Sudoxicam; Sulindac; 
Suprofen; Talmetacin; Talniflumate; Talosalate; Tebufelone; 
Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; 
Tetrydamine; Tiopinac; Tixocortol Pivalate; Tolmetin; Tol- 
metin Sodium; Triclonide; Triflumidate; Zidometacin; and 
Zomepirac Sodium.
Growth Factors
In other embodiments, a nanotube modified implant is used 
to deliver a growth factor. Growth factors are typically 
polypeptides or fragments thereof that support the survival, 
growth, or differentiation of a cell. A nanotube modified 
implant described herein can be used to deliver virtually any 
growth factor known in the art. Such growth factors include 
but are not limited to angiopoietin, acidic fibroblast growth 
factors (aFGF) (GenBank Accession No. NP_149127) and
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basic FGF (GenBank Accession No. AAA52448), bonemor- 
phogenic protein (BMP)(GenBank Accession No. 
BAD92827), vascular endothelial growth factor (VEGF) 
(GenBank Accession No. AAA35789 or NP_001020539), 
epidermal growth factor (EGF)(GenBank Accession No. 
NP_001954), transforming growth factor a  (TGF-a) (Gen­
Bank Accession No. NP_003227) and transforming growth 
factor (3 (TFG-|3) (GenBank Accession No. 1109243A), 
platelet-derived endothelial cell growth factor (PD-ECGF) 
(GenBank Accession No. NP_001944), platelet-derived 
growth factor (PDGF)(GenBank Accession No. 1109245A), 
tumor necrosis factor a  (TNF-a)(GenBank Accession No. 
CAA26669), hepatocyte growth factor (HGF)(GenBank 
Accession No. BAA14348), insulin like growth factor (IGF) 
(GenBank Accession No. P08833), erythropoietin (GenBank 
Accession No. P01588), colony stimulating factor (CSF), 
macrophage-CSF (M-CSF)(GenBank Accession No. 
AAB59527), granulocyte/macrophage CSF (GM-CSF) 
(GenBank Accession No. NP_000749) and nitric oxide syn­
thase (NOS)(GenBank Accession No. AAA36365). In one 
preferred embodiment, the growth factor is BMP. In another 
embodiment, the agent is a statin that promotes bone growth. 
Exemplary statins include but are not limited to simvastatin, 
atorvastatin (Lipitor), cerivastatim, fluvastatin, lovastatin, 
and pravastatin.
Antimicrobial Agents
Staphylococcus aureus, staphylococcus epidermidis, and 
Pseudomonas aeruginosa are pathogens that are commonly 
present at musculoskeletal wound sites. S. aureus is often 
associated with prosthetic joint infection. The invention pro­
vides nanotube modified orthopedic implants useful in treat­
ing or preventing infection at a site of trauma. Any antimicro­
bial agent known in the art can be used in the nanotube 
modified implants of the invention at concentrations gener­
ally used for such agents.
Antimicrobial agents useful in nanotube compositions of 
the invention include but are not limited to antibacterials, 
antifungals, and antivirals. An antimicrobial agent as used 
herein is an agent which reduces or stabilizes the survival, 
growth, or proliferation of a pathogen. Antimicrobial agents 
include but are not limited to Aztreonam; Chlorhexidine Glu­
conate; Imidurea; Lycetamine; Nibroxane; Pirazmonam 
Sodium; Propionic Acid; Pyrithione Sodium; Sanguinarium 
Chloride; Tigemonam Dicholine; Acedapsone; Acetosulfone 
Sodium; Alamecin; Alexidine; Amdinocillin; Amdinocillin 
Pivoxil; Amicycline; Amifloxacin; Amifloxacin Mesylate; 
Amikacin; Amikacin Sulfate; Aminosalicylic acid; Ami­
nosalicylate sodium; Amoxicillin; Amphomycin; Ampicillin; 
Ampicillin Sodium; Apalcillin Sodium; Apramycin; Aspar- 
tocin; Astromicin Sulfate; Avilamycin; Avoparcin; Azithro­
mycin; Azlocillin; Azlocillin Sodium; Bacampicillin Hydro­
chloride; Bacitracin; Bacitracin Methylene Disalicylate; 
Bacitracin Zinc; Bambermycins; Benzoylpas Calcium; 
Berythromycin; Betamicin Sulfate; Biapenem; Biniramycin; 
Biphenamine Hydrochloride; Bispyrithione Magsulfex; 
Butikacin; Butirosin Sulfate; Capreomycin Sulfate; Carba- 
dox; Carbenicillin Disodium; Carbenicillin Indanyl Sodium; 
Carbenicillin Phenyl Sodium; Carbenicillin Potassium; 
Carumonam Sodium; Cefaclor; Cefadroxil; Cefamandole; 
Cefamandole Nafate; Cefamandole Sodium; Cefaparole; 
Cefatrizine; Cefazaflur Sodium; Cefazolin; Cefazolin 
Sodium; Cefbuperazone; Cefdinir; Cefepime; Cefepime 
Hydrochloride; Cefetecol; Cefixime; Cefinenoxime Hydro­
chloride; Cefmetazole; Cefmetazole Sodium; Cefonicid 
Monosodium; Cefonicid Sodium; Cefoperazone Sodium; 
Ceforanide; Cefotaxime Sodium; Cefotetan; Cefotetan Diso­
dium; Cefotiam Hydrochloride; Cefoxitin; Cefoxitin
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Sodium; Cefpimizole; Cefpimizole Sodium; Cefpiramide; 
Cefpiramide Sodium; Cefpirome Sulfate; Cefpodoxime 
Proxetil; Cefprozil; Cefroxadine; Cefsulodin Sodium; 
Ceftazidime; Ceftibuten; Ceftizoxime Sodium; Ceftriaxone 
Sodium; Cefuroxime; Cefuroxime Axetil; Cefuroxime Piv- 
oxetil; Cefuroxime Sodium; Cephacetrile Sodium; Cephal­
exin; Cephalexin Hydrochloride, Cephaloglycin; Cephalori- 
dine; Cephalothin Sodium; Cephapirin Sodium; Cephradine; 
Cetocycline Hydrochloride; Cetophenicol; Chlorampheni­
col; Chloramphenicol Palmitate; Chloramphenicol Pantoth­
enate Complex; Chloramphenicol Sodium Succinate; Chlo- 
rhexidine Phosphanilate; Chloroxylenol; Chlortetracycline 
Bisulfate; Chlortetracycline Hydrochloride; Cinoxacin; 
Ciprofloxacin; Ciprofloxacin Hydrochloride; Cirolemycin; 
Clarithromycin; Clinafloxacin Hydrochloride; Clindamycin; 
Clindamycin Hydrochloride; Clindamycin Palmitate Hydro­
chloride; Clindamycin Phosphate; Clofazimine; Cloxacillin 
Benzathine; Cloxacillin Sodium; Cloxyquin; Colistimethate 
Sodium; Colistin Sulfate; Coumermycin; Coumermycin 
Sodium; Curcumin; Cyclacillin; Cycloserine; Dalfopristin; 
Dapsone; Daptomycin; Demeclocycline; Demeclocycline 
Hydrochloride; Demecycline; Denofungin; Diaveridine; 
Dicloxacillin; Dicloxacillin Sodium; Dihydro streptomycin 
Sulfate; Dipyrithione; Dirithromycin; Doxycycline; Doxycy- 
cline Calcium; Doxycycline Fosfatex; Doxycycline Hyclate; 
Droxacin Sodium; Enoxacin; Epicillin; Epitetracycline 
Hydrochloride; Erythromycin; Erythromycin Acistrate; 
Erythromycin Estolate; Erythromycin Ethylsuccinate; Eryth­
romycin Gluceptate; Erythromycin Lactobionate; Erythro­
mycin Propionate; Erythromycin Stearate; Ethambutol 
Hydrochloride; Ethionamide; Fleroxacin; Floxacillin; Flu- 
dalanine; Flumequine; Fosfomycin; Fosfomycin 
Tromethamine; Fumoxicillin; Furazolium Chloride; Furazo- 
lium Tartrate; Fusidate Sodium; Fusidic Acid; Gentamicin 
Sulfate; Gloximonam; Gramicidin; Haloprogin; Hetacillin; 
Hetacillin Potassium; Hexedine; Ibafloxacin; Imipenem; Iso- 
conazole; Isepamicin; Isoniazid; Josamycin; Kanamycin Sul­
fate; Kitasamycin; Levofuraltadone; Levopropylcillin Potas­
sium; Lexithromycin; Lincomycin; Lincomycin 
Hydrochloride; Lomefloxacin; Lomefloxacin Hydrochlo­
ride; Lomefloxacin Mesylate; Loracarbef; Mafenide; Meclo- 
cycline; Meclocycline Sulfosalicylate; Megalomicin Potas­
sium Phosphate; Mequidox; Meropenem; Methacycline; 
Methacycline Hydrochloride; Methenamine; Methenamine 
Hippurate; Methenamine Mandelate; Methicillin Sodium; 
Metioprim; Metronidazole Hydrochloride; Metronidazole 
Phosphate; Mezlocillin; Mezlocillin Sodium; Minocycline; 
Minocycline Hydrochloride; Mirincamycin lydrochloride; 
Monensin; Monensin Sodium; Nafcillin Sodium; Nalidixate 
Sodium; Nalidixic Acid; Natamycin; Nebramycin; Neomy­
cin Palmitate; Neomycin Sulfate; Neomycin Undecylenate; 
Netilmicin Sulfate; Neutramycin; Nifuradene; Nifurald- 
ezone; Nifuratel; Nifuratrone; Nifurdazil; Nifurimide; 
Nifurpirinol; Nifurquinazol; Nifurthiazole; Nitrocycline; 
Nitrofurantoin; Nitromide; Norfloxacin; Novobiocin 
Sodium; Ofloxacin; Ormetoprim; Oxacillin Sodium; Oxi- 
monam; Oximonam Sodium; Oxolinic Acid; Oxytetracy- 
cline; Oxytetracycline Calcium; Oxytetracycline Hydrochlo­
ride; Paldimycin; Parachlorophenol; Paulomycin; 
Pefloxacin; Pefloxacin Mesylate; Penamecillin; Penicillin G 
Benzathine; Penicillin G Potassium; Penicillin G Procaine; 
Penicillin G Sodium; Penicillin V; Penicillin V Benzathine; 
Penicillin V Hydrabamine; Penicillin V Potassium; Pentizi- 
done Sodium; Phenyl Aminosalicylate; Piperacillin Sodium; 
Pirbenicillin Sodium; Piridicillin Sodium; Pirlimycin Hydro­
chloride; Pivampicillin Hydrochloride; Pivampicillin Pamo­
ate; Pivampicillin Probenate; Polymyxin B Sulfate; Porfiro-
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mycin; Propikacin; Pyrazinamide; Pyrithione Zinc; 
Quindecamine Acetate; Quinupristin; Racephenicol; 
Ramoplanin; Ranimycin; Relomycin; Repromicin; Rifabu­
tin; Rifametane; Rifamexil; Rifamide; Rifampin; Rifapen- 
tine; Rifaximin; Rolitetracycline; Rolitetracycline Nitrate; 
Rosaramicin; Rosaramicin Butyrate; Rosaramicin Propi­
onate; Rosaramicin Sodium Phosphate; Rosaramicin Stear­
ate; Rosoxacil; Roxarsone; Roxithromycin; Sancycline; San- 
fetrinem Sodium; Sarmoxicillin; Sarpicillin; Scopafungin; 
Sisomicin; Sisomicin Sulfate; Sparfloxacin; Spectinomycin 
Hydrochloride; Spiramycin; Stallimycin Hydrochloride; 
Steffimycin; Streptomycin Sulfate; Streptonicozid; Sulfa- 
benz: Sulfabenzamide; Sulfacetamide; Sulfacetamide 
Sodium; Sulfacytine; Sulfadiazine; Sulfadiazine Sodium; 
Sulfadoxine; Sulfalene; Sulfamerazine; Sulfameter; Sul­
famethazine; Sulfamethizole; Sulfamethoxazole; Sulfa- 
monomethoxine; Sulfamoxole; SulfanilateZinc; Sulfanitran; 
Sulfasalazine; Sulfasomizole; Sulfathiazole; Sulfazamet; 
Sulfisoxazole; Sulfisoxazole Acetyl; Sulfisoxazole Diola- 
mine; Sulfomyxin; Sulopenem; Sultamicillin; Suncillin 
Sodium; Talampicillin Hydrochloride; Teicoplanin; Tema- 
floxacin Hydrochloride; Temocillin; Tetracycline; Tetracy­
cline Hydrochloride; Tetracycline Phosphate Complex; 
Tetroxoprim; Thiamphenicol; Thiphencillin Potassium; 
Ticarcillin Cresyl Sodium: Ticarcillin Disodium; Ticarcillin 
Monosodium; Ticlatone; Tiodonium Chloride; Tobramycin; 
Tobramycin Sulfate; Tosufloxacin; Trimethoprim; Trimetho­
prim Sulfate; Trisulfapyrimidines; Troleandomycin; Tros- 
pectomycin Sulfate; Tyrothricin; Vancomycin; Vancomycin 
Hydrochloride; Virginiamycin; Zorbamycin; Difloxacin 
Hydrochloride; Lauryl Isoquinolinium Bromide; Moxalac- 
tam Disodium; Ornidazole; Pentisomicin; and Sarafloxacin 
Hydrochloride.
Delivery of Nanotube Compositions
Nanotube modified implants can be delivered by any 
method known to the skilled artisan. In one approach, a nano­
tube modified implant is surgically implanted at a site where 
a dental implant, orthopedic implant, cardiovascular implant, 
neurological implant, neurovascular implant, gastrointestinal 
implant, muscular implant, cochlear implant, and ocular 
implant is required. If desired, the nanotube modified implant 
is loaded with one or more antibiotics or other biologically 
active agents by a clinician. In one embodiment, a biologi­
cally active agent is loaded into nanotube by placing the 
implant into a vacuum chamber that also has the capability of 
depositing the agents onto the surface. Devices for vacuum 
depositing compounds on surfaces are known in the art. As 
the vacuum is slowly decreased toward ambient pressure the 
agent is deposited into the nanotube.
Kits
The invention provides kits that include nanotube modified 
implants. In one embodiment, the kit includes a nano tube 
modified implant containing a therapeutic or prophylactic 
agent that that prevents or treats infection (e.g., an antimicro­
bial agent) or that promotes healing (e.g., growth factor, anti­
inflammatory, clot promoting agent, anti-thrombotic). In 
some embodiments, the kit comprises a sterile container 
which contains a nanotube modified implant; such containers 
can be boxes, ampoules, bottles, vials, tubes, bags, pouches, 
blister-packs, or other suitable container forms known in the 
art. Such containers can be made of plastic, glass, laminated 
paper, metal foil, or other materials suitable for holding medi­
caments.
If desired a nanotube modified implant of the invention is 
provided together with instructions for using it in a prophy­
lactic or therapeutic method described herein. The instruc­
tions will generally include information about the use of the
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composition for the treatment of a trauma, infection or related 
disease in a subject in need thereof. The instructions may be 
printed directly on the container (when present), or as a label 
applied to the container, or as a separate sheet, pamphlet, 
card, or folder supplied in or with the container. 
Electrochemical Etching Device and System
The invention provides a device for selectively modifying 
a surface to generate nano tubes. In one embodiment, the 
device features one or more cathodes (e.g., graphite), one or 
more anodes (e.g., graphite) and a titanium or titanium alloy 
surface in an electrolyte solution, wherein the anode is in 
proximity to the surface; at least one power supply in electri­
cal communication with the cathode and anode(s), such that 
when voltage is applied in the presence of an electrolyte 
solution nanotubes are formed on the surface; and a support 
for positioning the cathode and one or more anodes relative to 
the surface. In one embodiment, the cathode and/or anodes 
are point or cylindrical electrodes that can be positioned 
relative to selected sites on the surface. In another embodi­
ment, the distance of the cathode and/or anodes relative to the 
surface is varied, the voltage applied is varied, and the dura­
tion for which the voltage is applied is varied. The voltage, 
time, and distances are selected to form nanotubes whose 
length and/or diameter differs between sites on the surface.
The invention provides an automated system for etching a 
titanium or titanium alloy surface to form nanotubes at one or 
more selected sites on the surface. In one embodiment, the 
device features a support for positioning the cathode and one 
or more anodes relative to a titanium or titanium alloy surface; 
a cathode and one or more anodes in electrical communica­
tion with said power supply; wherein when voltage is applied 
in the presence of an electrolyte solution nanotubes are 
formed at selected sites on the surface; and a control device 
for detecting the electrical resistance and current within the 
system, wherein the control device is configured to control- 
lably adjust the distances, voltages, and times used to form 
nanotubes at selected sites on the surface.
If the etching electrical current is measured to very high 
precision over time the current within the system can serve as 
a feedback signal to the automated machine control system 
correlating with one or more of the following: nanotube diam­
eter, nanotube length, projected area of titanium removed 
between nanotubes and within their inner diameter, and vol­
ume of titanium removed from between nanotubes and within 
their inner diameter. This feedback signal automatically alters 
electrode position, distance from the surface, voltage, and the 
time for which the voltage is applied to achieve nanotubes 
having the desired dimensions, mechanical stiffness, or other 
properties.
The following examples are put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how to make and use the assay, screening, and 
therapeutic methods of the invention, and are not intended to 
limit the scope of what the inventors regard as their invention.
EXAMPLES 
Example 1
Ti Nanotube Fabrication Using Anodization
Nanotubes were fabricated onto/into the surface of pure 
and Ti6A14V titanium sheets and Ti6A14V ELI orthopedic 
hardware by anodization. Titanium and titanium alloy sur­
faces comprising nanotubes were studied for the purpose of
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enhancing cell growth and adhesion on titanium surfaces. 
Methods were developed to fabricate the nanotubular struc­
tures on titanium surfaces.
T i02 nanotubes were synthesized from titanium substrates 
using anodization. The fabrication process used an etching 
set-up involving a Ti anode, a counter electrode; electrolyte, 
and a DC power source (FIG. 1). The substrates for nanotube 
etching were flat, 2 cmx3 cm and 0.25 mm thick, andpolished 
with 0.06 mm colloidal S i02. Prior to nanotube etching, the 
substrates were sequentially sonicated in acetone, isopropyl 
alcohol, and methanol, then rinsed with deionized water, and 
dried in an N2 stream. The experimental setup consisted of a 
two-electrode arrangement. Four different metals (platinum, 
stainless steel, copper, and graphite) were used as the counter 
electrodes for four different sets of anodizations. The spacing 
between the substrates and the counter electrode was approxi­
mately 25 mm. The anodization was carried out at room 
temperature. The electrolyte was 0.2 wt % solution of NH4F 
in 49 ml ethylene glycol and 1 ml deionized water (49 mL 
ethylene glycol, 1 mL water, and 0.33 grams of ammonium 
fluoride). The electrolyte used is benign compared to previ­
ously reported electrolytes of hydrofluoric acid and nitric 
acid. The innocuous etching electrolyte (NF14F and ethylene 
glycol rather than F1F), makes the process considerably safer, 
cheaper, and easier to maintain by eliminating the need for 
costly specialized environmental containment and disposal 
safeguards. Additionally, it ensures that any residual chemical 
etchant that might cling to the product surface would be 
essentially benign. A constant 60 V DC was used for all 
experiments. After anodization, the samples were rinsed with 
deionized water and dried in a N2 stream.
Nanotubes formed by different counter electrodes were 
analyzed by scanning electron microscopy (SEM) and 
energy-dispersive X-ray spectroscopy (EDS) (FIGS. 2A-2B). 
SEM analysis showed nanotubes were formed when commer­
cially pure (cp) Ti was used as anode and Pt as counter 
electrode (FIG. 2A). As shown by the EDS analysis, T i02 
nanotubes using Pt as counter electrode were pure with no 
traces of other elements. SEM analysis showed nanotubes 
were formed when cp Ti was used as anode and stainless steel 
as the counter electrode (FIG. 2B). As shown by the EDS 
analysis, T i02 nanotubes using stainless steel as counter elec­
trode have some traces of Fe and Cr and are not pure. SEM 
analysis showed nanotubes were formed when cp Ti was used 
as anode and Cu as counter electrode (FIG. 2C). As shown by 
the EDS analysis, T i02 nanotubes formed using copper as the 
counter electrode are pure with no traces of Cu element. SEM 
analysis showed nanotubes were formed when cp Ti was used 
as anode and graphite as counter electrode (FIG. 2D). As 
shown by the EDS analysis, T i02 nanotubes using graphite as 
counter electrode are pure with no traces of other elements.
Taking into consideration the fact that Pt is an expensive 
metal, substituting Pt in the counter electrode has the poten­
tial to reduce the cost of nanotube fabrication. Moreover, 
materials other than Pt may provide additional advantages. 
For example, graphite can also be easily shaped into a point 
electrode, thus, allowing the use of multiple graphite counter 
electrodes. Additionally, replacing a single Pt electrode with 
multiple and individually addressable graphite electrodes sig­
nificantly lowers the operating cost of the process (over 
5000x electrode price differential) while increasing versatil­
ity.
Due to the very high cost of platinum and the undesirable 
effects of stainless steel and copper electrodes, graphite was 
chosen for all future work. In a typical apparatus whereby 
uniform nanotubular structures are produced on a titanium 
specimen, the platinum specimen is connected to +60 VDC
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and the graphite electrode is connected to electrical ground 
(FIG. 3). The platinum and graphite electrode are placed in 
the ammonium fluoride electrolyte and the circuit is ener­
gized. Typical nanotubular structures were produced under 
these fabrication conditions using graphite electrodes (FIG. 
4). Additionally, under this apparatus configuration, repro­
ducible results with quantifiable relationships among anod­
ization time, voltage, electrode standoff distance and geomet­
ric complexity of the implant surface were obtained. Surface 
morphologies ranged from continuous and porous to multiple 
and independent vertical nanotubes (FIGS. 5A and 5B). Volt- 
age/time data indicate aspect ratio & tube wall conditions can 
be controlled (Table 1).
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TABLE 1
Effect o f anodization time and voltaae on TiO-, nanotube lensth.
Time
Voltage 4 Hrs 8 Hrs 16 Hrs
20 V 589 nm 1,070 nm 1,388 nm
40 V 1,443 nm 4,530 nm 6,114 nm
60 V 5,493 nm 6,754 nm 10,075 nm
Thus, nanotubular structures were fabricated using inex­
pensive graphite cylindrical rods (rod electrodes) and electri­
cally insulating coated graphite rods leaving only the tip 
uncoated (point electrodes) in place of expensive platinum 
sheet electrodes. The nanotubular structures were fabricated 
using a separation distance between the titanium and graphite 
that can vary from close proximity to up to 100 mm, without 
limitation. Ti nanotubes were quickly fabricated with increas­
ing anodization voltage up to +60 VDC.
Example 2
Nanotube Annealing Increases Wettability of T i02 
Nanotube Surfaces
This study examined the effect of annealing and ageing on 
the wettability of T i02 nano tube surfaces (TNT) fabricated by 
anodization. The wettability of a surface is important in aque­
ous cell growth since a hydrophobic (non-wettable) surface 
will repel water and cause it to bead-up. Commercially pure 
and grade-5 (Ti6A14V) titanium alloy foils were used to fab­
ricate T i02 nanotubes. Post-anodization thermal treatment 
was at 450° C. using a rapid thermal annealer. A heating/ 
cooling rate o f308° C./min was used, and the substrates were 
annealed in air at 450° C. for 3 hours. The annealing treatment 
resulted in phase transformation of nanotubes from amor­
phous to crystalline anatase. Thermally treated surfaces were 
analyzed by TEM and compared to surfaces without treat­
ment (FIGS. 6A-6B). Thermally treated surfaces had 
annealed T i02 nanotubes compared to surfaces without treat­
ment, which had amorphous nanotubes.
Water droplets (one-microliter) were used to define the 
wettability of the TNT surfaces by measuring the contact 
angles. One-microliter of de-ionized (DI) water was slowly 
deposited on the surfaces by a screw syringe. The experi­
ments were repeated five times for each measurement. The 
temperature and humidity were maintained at 24±0.5° C. and 
21 ±1%, respectively. Priorto the experiments, droplet depo­
sition was repeatedly tested to ensure that the water droplets 
had consistent shapes.
During the experiment, a droplet was dynamically 
recorded on an image capturing system via a CCD camera.
Water droplets were placed on bare Ti foil, pure TNT, and 
alloy TNT in as-synthesized and annealed conditions (FIG. 
7A). Images of droplets on the surfaces were captured five to 
ten times for each case and the corresponding contact angles 
calculated. A digital image analysis algorithm was developed 
to obtain contact angles, contact radii, and center-heights of 
the droplets on the nano tube surfaces.
Data were plotted to show the trend of the contact angle 
variation (FIG. 7B). Three observations were made from the 
wettability experiments. The first was the difference between 
the contact angles of the bare pure and bare alloy titanium 
foils. In the case of pure titanium, the contact angles were 
larger than the alloy. Second, it was found that the creation of 
TNT structures made the surface more hydrophilic. In all 
cases after the anodization process, the droplet contact angles 
decreased in the range of 55-70% compared to the contact 
angles of each bare foil. The third phenomenon was that the 
annealing made the TNT surfaces super-hydrophilic. In gen­
eral, annealing metal generates a hydrophobic surface. Sur­
prisingly and unexpectedly, annealing produced super-hydro­
philic surfaces. The water droplet contact angles on the 
annealed TNT surfaces decreased 40-56% compared to the 
as-anodized TNT surface cases. The annealing resulted in 
nanotubes of anatase causing super-hydrophilic surfaces to 
be generated.
The effect of ageing of the TNT surfaces on wettability was 
examined during and after three months (FIG. 8). Water drop­
lets were placed on bare titanium, as-anodized TNT, and 
annealed TNT after ageing. For the TNT surfaces, it was 
found that the surface wettabilities changed from hydrophilic 
to hydrophobic or from super-hydrophilic to hydrophilic after 
ageing. All of the TNT surfaces had the same tendency and 
the resulting water droplet contact angles are shown in Table 
2 .
TABLE 2
22
Variation o f contact angle with respect to time
Contact angle (°) 0 day 22 day 51 day 92 day
Annealed Pt Pure 10.76 21.85 23.39 26.94
TNT Alloy 14.59 19.45 31.56 44.12
As-grown Pt Pure 24.62 28.25 34.05 42.47
TNT Alloy 32.39 37.97 42.23 80.35
Bare Pure 82.52 74.63 78.66 81.24
Alloy 67.07 54.84 73.48 56.80
The contact angle analyses were made 22, 51, and 92 days 
after fabrication. The hydrophobicity increased at different 
rates for each case, but all of the water droplet contact angles 
increased on the TNT structured surfaces. Data were plotted 
to show the variation of contact angles for the cases of the 
annealed and as-anodized TNT surfaces (FIG. 9A). Invari­
ably, the results show that the surface hydrophobicity was 
increased for all four cases.
T i02 has hydrophobic characteristics. Without being 
bound to a particular theory, as time passed, the hydropho­
bicity increased. The change in the wetting behavior of T i02 
porous structures provides advantages in various applica­
tions. For example, there is often high sensitivity to different 
wetting characteristics that affect the biological responses of 
protein adsorption, cell affinity or cell adhesion on a surface. 
For bare titanium and alloy, wettability does not change as a 
function of ageing (FIG. 9B). The measured contact angles of 
droplets remained nearly unchanged for each case. Without 
being bound to a particular theory, at the early stage, the 
contact angles decreased a small amount due to the initial
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oxidation of the metal. Before the experiment, the initial 
titanium foils were cleaned with ethanol and acetone. These 
samples then became oxidized through exposure to the air. An 
initial decrease of the contact angles was observed. However, 
the wettabilities of the bare titanium foils remained constant 
with respect to time after this initial change.
Thus, bare titanium foil is inherently hydrophobic, having 
an approximately 60-80 degree contact angle. Untreated T i02 
nanotube surfaces (as-anodized) were more hydrophilic than 
titanium foil. Annealing T i02 nanotube surfaces by heat treat­
ment further increased the hydrophilic property. However, 
T i02 nanotube surface became more hydrophobic when aged 
in air. These results indicate that where surface wettability is 
an advantage, using the anodization process described herein 
can grow nanotubes having this property. This process pro­
vides a potential application for producing orthopedic 
implants where the wettability characteristics of the surface 
can be specified.
Example 3
Nanotube Growth Inhibition with Multiple 
Electrodes
Using conventional electrochemical etching, nanotubular 
structures are fabricated on titanium surfaces by anodization. 
Without being bound to a particular theory, when current is 
applied, in the electrochemical etching apparatus an electric 
field emanates from a sheet electrode perpendicular to the 
surface of that sheet at all locations and traverse the electro­
lyte to the titanium specimen. The field lines enter the tita­
nium specimen, regardless of shape, perpendicular to the 
localized surface at all locations on the specimen. Without 
being bound to a particular theory, the uniformity of these 
field lines at the specimen (not at the electrode) produces the 
fabricated nanotubular structures.
Again, without being bound to a particular theory, if the 
electrode is a cylindrical rod or point the field lines will 
emanate from that rod or point in a more concentrated man­
ner, but will expand toward the much larger titanium speci­
men and enter that specimen as described above. If the elec­
trode is extremely close to the specimen, the field lines may 
lack complete uniformity as they enter the specimen.
Nanotubular structures are fabricated on the specimen 
where the voltage potential of the specimen is higher than 
surrounding electrodes. This is defined as “current leaving” 
the specimen—that is charge is moving from a more positive 
voltage to a lower voltage at any location on the titanium 
specimen. If however, “current enters” the titanium specimen 
at any location, nanotube fabrication is inhibited. Underthese 
specified fabrication conditions, the specimen may or may 
not be electrically connected to the electrochemical etching 
circuitry. The specimen may be allowed to electrically “float” 
(not be connected to the circuit) without imposing a particular 
voltage.
This innovation provides a method for locally inhibiting 
nanotube etching. If an electrode rod or point is placed in 
immediate proximity to the specimen surface, the electric 
field emanating from that electrode may not disperse to the 
entire specimen if there are other electrodes in close proxim­
ity at other voltage potentials (FIG. 10). Here, the titanium 
specimen is allowed to electrically float (it is not connected to 
the circuit).
A positive graphite rod electrode 3 mm diameter was 
placed 6 mm from the titanium specimen. The graphite elec­
trode was connected to +60 VDC. The portion of the titanium 
sheet specimen immersed in the electrolyte was 44 mm wide
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by 25 mm high and was not electrically connected. A second 
3 mm graphite electrode was placed on the other side of the 
specimen from the first electrode at a distance of 70 mm from 
the specimen and was connected to electrical ground. Fabri­
cation was allowed to continue for 97 minutes. Without being 
bound to a particular theory, a portion of the total current 
flowing from the positive to the ground electrode enters the 
specimen on the side nearest the positive electrode. The cur­
rent entering the specimen on the positive electrode side will 
leave the specimen as it seeks the ground potential. This 
leaving current will do so primarily on the ground electrode 
side of the specimen, but a small portion of the leaving current 
may leave at or near the sides of the specimen at some dis­
tance from the positive electrode. Current does not leave the 
specimen in the proximity of the positive electrode. There­
fore, nanotube fabrication is inhibited on the side nearest the 
positive electrode (FIG. 11).
To better understand the prior result, an experiment was 
conducted where the position of the titanium specimen was 
moved in relation to the arrangement of the electrodes (FIG. 
12). The voltage was +60 VDC and the specimen was allowed 
to electrically float. The fabrication duration was 60 minutes. 
Without being bound to a particular theory, the maj ority of the 
current flows directly from the positive to the negative elec­
trode. However, the electrolyte has a relatively low electrical 
conductivity owing to its chemical makeup. Therefore, a por­
tion of the current emanating from the positive electrode 
flows outward and enters the specimen primarily on one side. 
Nanotube fabrication is inhibited over most of this proximal 
side (FIG. 13). However, the current entering the specimen 
leaves it on the opposing side and nanotube fabrication takes 
place (FIG. 13).
As a further demonstration, a set-up was used where the 
position of the titanium specimen was moved into close prox­
imity to both electrodes (FIG. 14). The voltage was +60 VDC 
and the fabrication duration was 30 minutes. Without being 
bound to a particular theory, current enters the specimen near 
the positive electrode inhibiting nanotube fabrication (FIG. 
15). Current leaves the specimen on the opposing side of the 
specimen and other locations on the electrode side that are 
away from the positive electrode. All of the leaving current 
fabricates nanotubes (FIG. 15).
From these results, using large graphite rod electrodes 
(typically 3 mm in diameter) and placed relatively far from 
the specimens (typically 6-12 mm away), it was appreciated 
that if the graphite electrodes are made as smaller rods or 
points and placed at a closer proximity, inhibiting the fabri­
cation of nanotubes locally on the specimen surface is 
attained at a higher resolution of placement. It was also appre­
ciated that if after some duration of nanotube fabrication and 
inhibition time, the polarity of the positive graphite electrode 
is made negative while at the same time the specimen polarity 
is made positive, then nanotubes continue to be fabricated 
uniformly over the entire surface providing one or more 
regions of relatively long nanotubes and one or more regions 
of shorter nanotubes, based on the total time and current flow 
direction of each region. Each region corresponds to one or 
more graphite electrodes (e.g., an array of electrodes). Spe­
cialized physical locating equipment and electrical voltage 
control systems that are in common commercial use can be 
used to achieve this type of system.
In one embodiment, the automated system comprises an 
automated supporting system to hold the titanium implant 
(FIG. 16). The automated supporting system can support the 
implant from the top or can be a cradle-like structure from the 
bottom. In either case, the support provides electrical contact 
with the implant to form one side of the electrochemical
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etching cell. The bottom structure can be multiple indepen­
dently moved pins with the locations based on the implant 
being processed. The geometric descriptions of implants are 
contained in common computer aided design (CAD) systems 
where the shape and extent of the surface is expressed math­
ematically as a series of 3-D coordinates. Knowing the 
implant to be processed, the system positions the supporting 
pins appropriately. The pins may be moved by any means of 
electromechanical actuation such as a ball screw or pneu­
matic actuation. The supports are electrically insulated except 
for the tip(s) which contact the implant as shown. These 
supports are electrically common forming the anode side of 
the circuit. Again, knowing the shape of the implant from the 
CAD (or other) representation the individually addressable 
point etching electrodes are positioned and energized. Based 
on the nanotube dimensions desired at each particular loca­
tion the voltage, etch time, and standoff distance is calculated 
and automatically applied until the desired nanosurface is 
produced (see, e.g., Table 1)
In additional and further embodiments, the etching current 
of each electrode vs time is used to produce the desired 
surface (FIG. 29). As the nano tubes form, the metal surface 
becomes more porous as material is removed. Without being 
bound to a particular theory, this results in a progressively 
higher surface electrical resistance which, for each individu­
ally addressable voltage, results in a decreasing etching cur­
rent. The feedback signal can be used to individually halt 
etching for each electrode and/or to change the voltage and/or 
distance of each electrode based on the rate of change of the 
etching current. The fully implemented automated system 
may have many individual electrodes (e.g., an array of elec­
trodes), not all of which are used for a specific implant. 
Additionally, a system may have multiple implementations of 
the schematic to simultaneously process multiple implants of 
the same or different geometries.
Thus, a prescribed surface nanomorphology can be 
achieved by actively locating multiple point or cylindrical 
electrodes at prescribed distances, voltages, and times at dif­
ferent locations on the surface of the implant. Additionally, by 
using multiple graphite electrodes, and by selecting the volt­
age of each electrode and the titanium, nanotube fabrication 
can be allowed in selected regions of the titanium and inhib­
ited in other selected regions of the titanium. These results can 
be further extended to include varying both voltage and time 
of each of the multiple electrodes (e.g., an array of electrodes) 
to fabricate nanotubular structures of selected varying 
lengths.
Example 4
Osteoblast Growth and Environment on Nanotube 
Surfaces
In vitro experiments were conducted to investigate cell 
density of MC3T3-E1 mouse osteoblasts (CRL-2593, sub­
clone 4, ATCC USA). An aliquot of cells (1 ml) was mixed 
with alpha minimum essential medium (a-MEM, 10 ml; 
Invitrogen, USA) with 10 vol. % fetal bovine serum (FBS; 
Invitrogen, USA) and 1 vol. % penicillin-streptomycin (PS; 
Invitrogen, USA). The cell suspension was placed in a cell 
culture dish and incubated at 37° C. and 5 vol. % C 0 2 envi­
ronment. The concentration of the MC3T3-E1 osteoblastic 
cells was checked under an optical microscope every 24 hrs 
until it reached its saturation point of approximately 3000 
cells/mm2 after 72 hrs of incubation. When the cells reached 
their confluent point they were ready to be subcultured on 
T i02 nanotube substrates or bare control substrates. The
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MC3T3-E1 cells were seeded onto the experimental substrate 
of interest and were placed on a 30-well polystyrene plate and 
stored in a 37° C. C 0 2 incubator for 24, 48 and 72 hrs to 
observe the cell morphology and count the number of cells 
attached as a function of incubation time. Samples of com­
mercially pure Ti (cp Grade 2) and Ti6A14V (Grade 5), with 
and without nanotubes were used to investigate the effect of 
nano tubes on adhesion, and cell density of osteoblasts. These 
two types of samples were chose based on the strong estab­
lishment of Ti implants in orthopedics and their preferred 
mechanical and biological properties.
A field-emission SEM was used for the morphological 
characterization of the substrates. The length of the nanotubes 
was determined from cross-section images. EDS chemical 
composition data were collected to investigate the composi­
tion of individual nanotubes and to confirm alloy nanotube 
composition characteristics ofTi, Al, andV. Further morpho­
logical and structural characterization of the T i02 nanostruc­
tures were carried out with a TEM operated at 200 keV. After 
evaluating the cell density and adhesion on T i02 nanotubes, 
cell counts were conducted. By rapid rinsing with a phosphate 
buffered saline (PBS) solution and fixation of the cells (de­
scribed below) and immediate SEM imaging of the substrate, 
only the attached cells were counted toward the cell density. 
The high-resolution imaging gave the capability of distin­
guishing between non-flat and well-spread flat cells and the 
rinsing followed by rapid fixation removed the non-adherent 
cells, resulting in a more accurate cell count assay. The num­
ber of cells in an SEM image was counted by software. Five 
random fields were counted per substrate and all experiments 
were run in triplicate, repeated at least three times. The cell 
count variability was ±5 cells/mm2. The mean numbers of 
total attached cells were calculated from the total cell number 
counted from 5 random square areas (1.Oxl.O mm2) of each 
18 different substrates. The mean numbers of attached cells 
on the surfaces of the control and nanotube covered samples 
were compared for 24, 48 and 72 hrs of incubation.
For the FIB and SEM investigations, the cells were fixed on 
the nanotube substrates. After 72 hrs of culture the medium 
was replaced with 10 ml of 90% ethanol and after 10 min the 
ethanol was pipetted out and the substrates were left to air dry 
at 37° C. for 15 min. Substrates with fixed cells were inserted 
into the specimen chamber of a FIB (Flitachi SA-2000). The 
rough milling conditions to open a trench in the cell, used ion 
currents of 5 to 7 nA at 30 kV. Lower beam currents of 100 to 
670 pA were used to polish the cross section. Beam dwell 
time for milling was 3 ps.
The density of MC3T3 cells after up to 72 hrs of incubation 
on T i02 nano tubes with varying crystallinity and anodization 
duration was measured. The density of adhered cells on amor­
phous and crystalline T i02 nanotube surfaces was compared 
with control bare surfaces for both cp and alloy substrates 
(FIG. 17). On the bare control cp-Ti substrate, cell density 
increased from 40 cells/mm2 after 24 hrs to 300 cells/mm2 
after 72 hrs of incubation. The presence of nanotubes 
enhanced cell density from 80 cells/mm2 after 24 hrs to 900 
cells/mm2 after 72 hrs of incubation. In the case of annealed 
cp-Ti02 nanotubes the cell density increased from 300 cells/ 
mm2 after 24 hrs to 2500 cells/mm2 after 72 hrs of incubation. 
These results show that annealed nanotubes enhanced cell 
density from 900 cells/mm2 in amorphous (ω-anodized) 
nanotubes to 2500 cells/mm2 in annealed nanotubes after 72 
hrs of incubation. In addition, on the bare control Ti6A14V 
substrate cell density increased from 12 cells/mm2 after 24 
hrs to 200 cells/mm2 after 72 hrs of incubation. However, the 
results indicate that nanotube morphology enhanced cell den­
sity from 40 cells/mm2 after 24 hrs to 800 cells/mm2 after 72
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hrs of incubation. This enhanced cell density is in agreement 
with the results on cp-Ti and cp-Ti02 nanotubes.
However, the total cell density in the control Ti6A14V and 
alloyed-Ti02 nanotubes was slightly lower for all incubation 
periods, in comparison to the total cell density in cp-Ti and 
cp-Ti02 nano tubes. Without being bound to a particular 
theory, this may be due to slightly lower biocompatibility of 
the alloying elements (Aluminium and Vanadium) and their 
oxides. Also, longer anodization duration resulted in longer 
and more flexible nanotubes. Without being bound to a par­
ticular theory, the surface of bare control samples showed the 
lowest cell density, because the surface of bare control 
samples has a very high mechanical stiffness (essentially the 
elastic modulus of Ti). As the length of the nanotubes 
increased beyond the length defined by an etching time of 4 
hours, the cell density decreased (FIG. 18). This result indi­
cates that there is an optimal nanotube length associated with 
optimal bending stiffness.
FIB Milling Studies at Cell-Nanotube Interfaces
Focused ion beam (FIB) milling studies at cell-nanotube 
interfaces provided evidence of the cell filopodia growth 
inside the nanotubes, demonstrating a strong interlock 
between the cell and substrate.
Initially, fibroblast adhesion to T i02 nanotubes was exam­
ined by the FIB method and then this assay was extended to 
osteoblast cells. The main reason to select fibroblasts for the 
initial FIB work was that these cells make strong bonds with 
most substrate materials. In addition, fibroblast cells are the 
first to bond with the surface of the implant in in-vivo appli­
cation of biomedical implants.
FIB milled fibroblast cells were obtained from a primary 
ion beam (FIGS. 19A and 19B). The results show that fibro­
blast filopodia strongly interacted with the cell’s nano-envi- 
ronment. Internal structures, membranes and morphological 
stability and integrity are shown by the FIB method. The 
interface between the cell and the substrate was observed in 
the magnified cross sectional view of the cell-nanotube inter­
face (FIGS. 20A-20D). After milling the cell by FIB, the 
filopodia appeared to grow into the nano tubes. The results 
also revealed that fibroblast sustained very high vacuum with­
out visible damage and they physically survived ion beam 
milling and imaging. Moreover, ion milling revealed many 
internal features of cells at the submicron scale as well as the 
high interaction and growth of the cells among the nanotubes.
The same FIB and SEM method was adapted to evaluate 
osteoblast cell attachment and surface interaction. The inter­
action of MC3T3 osteoblast cells with T i02 nanotubes was 
analyzed by SEM (FIGS. 21B and 21C). The extension of 
osteoblast cells for adhesion on the nanotubes, as well as cell 
clusters (FIG. 21A) on the nanotube substrates, indicated the 
ability of the nanotube structure to promote cell adhesion and 
growth. As observed in the SEM images, the surface tended to 
induce cell number, attachment, and spreading. The osteo­
blast cells had a fully spread morphology (FIG. 21A) as well 
as expansion of cell filopodia (FIGS. 21B and 21C). Attach­
ment of cell filopodia to the nanotubes and filopodia expan­
sion between the nanotubes was also observed. Thus, the 
nano tubes acted as anchors for cell filopodia to grab (FIGS. 
21F and 21G), increase spreading (FIG. 21D), and improve 
attachment (FIG. 21G).
The evaluations of cell anchorage and interlock were per­
formed by FIB milling and SEM. The architecture of the 
cell/substrate interface was visualized by SEM (ion beam 
imaging resolution is lower) to provide better insight into the 
morphological and functional features of interfacial osteo­
blast cell attachment. SEM images of the FIB milled cells 
revealed that the nanotubes were completely clogged by the
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cells (FIGS. 22A-22D). Even after removal of the cell top 
section by FIB (FIGS. 22C and 22D) the nanotubes remain 
clogged (FIGS. 22E and 13F) approximately 5 nm in depth 
(FIG. 14). Clogging is due to high attachment of the cells 
(qualitatively indicated from SEM images in FIGS. 21A-21G 
and 22A-22E), indicating the well spread cell morphology 
and the cell growth inside the hollow section of the nanotubes 
(FIG. 23). The osteoblasts were in direct cell/substate con­
tact with the nanotubes and were firmly attached to the sub­
strate surface (FIGS. 22A-22E). EDS chemical analysis 
showed that the bond between the nanotubes and the adjacent 
osteoblast cell layer is composed of calcium and phosphorous 
elements which therefore seemed to mimic the bond in the 
bone tissue itself. On the substrate surface, cell filopodia and 
the extracellular matrix remained attached following separa­
tion from the milled top section of the cell (FIGS. 22A-22E 
and 23). These observations revealed a close interfacial con­
tact or direct contact between the osteoblasts and the nano­
tubes followed by calcium and phosphorous deposition on the 
nanotubes (FIG. 16). Calcium and phosphorous are the pri­
mary components of bone matrix. The deposition of calcium 
and phosphorous onto nanotubes was confirmed, indicating 
that nanotubes maintained osteoblast functionality (FIG. 23).
The SEM images (FIG. 21G) and EDS analysis (FIG. 23) 
showed that extracellular matrix (ECM) was secreted over the 
surface of the sample and deposition of calcium and phos­
phorous on the nanotubes, respectively. The cellular activity 
of osteoblasts on the surface initiates with deposition of cal­
cium and phosphorous as primary components of bone 
matrix. This production of ECM on the nanotubes was 
observed to be the result of osteoblast migration and health 
cellular activity. Without being bound to a particular theory, 
the nano tubes act as anchors for the cell filopodia to grab onto 
and facilitate cell migration along the surface. The anchorage 
benefit of nanotubes together with their strong hydrophilic 
properties contributed to increased osteoblast density, spread­
ing and attachment and achieved high-cohesion osseointegra- 
tion.
The osteoblast cell culture experiments on the substrates 
without nanotubes and substrates with nanotubes indicated 
the presence of nanotube morphology increased cell density. 
The nanotubes act as anchors for the cell filopodia to grab 
onto and have facilitated migration along the surface. The 
deposition of calcium and phosphorous which are the primary 
components of bone matrix onto nanotubes indicates that 
nanotubes have maintained osteoblast functionality. In view 
of nanotube structure, the crystalline anatase nanotubes were 
more effective in enhancing the cell growth in comparison to 
the amorphous nanotubes probably due to increased hydro- 
philicity. From a geometrical perspective, the nanotubes with 
the same crystalline structure and chemical composition, but 
lower anodization duration and consequently smaller length 
and diameter, showed higher cell density. The total cell den­
sity in the bare control cp-Ti (Grade 2) and cp-Ti02 nanotubes 
is slightly higher for all incubation periods, in comparison to 
the total cell density in bare control Ti alloy (Grade 5) and 
alloyed T i02 nanotubes. This behavior may be explained by 
slightly lower biocompatibility of the alloying elements (A1 
and V) and their oxides. EDS chemical analysis suggested 
that the bond between the nanotube substrate and the adjacent 
osteoblast cell layer is composed of calcium and phosphorous 
elements which therefore seemed to mimic the bond in the 
bone tissue itself. Based on FIB results, on the nanotube 
covered surfaces, cells were observed to extend protrusions in 
both the lateral and vertical directions, growing not only on 
top of the nanotubes but also between and potentially down 
into the open nanotube pores. This anchorage benefit of nano-
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tubes together with their strong hydrophilic properties 
appears to have increased osteoblast density, spreading and 
attachment for a promising high-cohesion osseointegration.
Example 5 5
Nanotube Fabrication on Orthopedic Bone Screws
To demonstrate the applicability of these processes in the 
orthopedic industry and to show the structural robustness, 10 
nanotubes were fabricated on Ti6A14V ELI orthopedic bone 
screws. These specimens were outdated surplus cancellous 
screws 6.5 mm OD and 3.2 mm ID (Linvatec of Laigo, Fla.).
Nanotubes were fabricated on the cancellous bone screws 
using the standard setup with the screw connected to the 15 
positive terminal and a graphite rod connected to electrical 
ground. An approximate 12 mm portion of the end of the bone 
screw was immersed into the electrolyte and the circuit was 
energized at +60 VDC. After 15 minutes, the screw was 
further immersed into the electrolyte an additional approxi- 20 
mately 12 mm for an additional 15 minutes of etching time. In 
this manner, the end portion of the screw had “30 minute 
nano tubes” and the middle portion of the screw had “15 
minute nano tubes.” The separation distance between the 
screw and graphite rod was approximately 100 mm. Nano- 25 
tubes were observed to be fabricated over all regions of the 
bone screws (FIGS. 24A and 24B).
Torque Insertion and Removal in Bone Simulant
To demonstrate the robustness of the nanotubes and to 
compare with predicted results from structural computer 30 
models, the nanotube covered bone screws were subjected to 
super-physiological forces that may be encountered during 
surgical implantation. Bone screws were selected because 
they experience shear and surface-normal forces during inser­
tion into bone that are greater than during normal patient use. 35 
Additionally, screw loosening is an implant failure mecha­
nism whereby increased bone adhesion can provide a solu­
tion.
Bone stimulant material (Sawbones 1522-03, 20 pounds 
per cubic foot polyurethane) had multiple pilot holes drilled 40 
into it with recommended diameters obtained from the litera­
ture for different conditions of bone. The pilot-hole diameters 
were 3.2 mm, 4.5 mm, 4.9 mm, and 5.0 mm. The bone screws 
have a thread root diameter of 3.2 mm and an outside thread 
diameter of 6.5 mm. Therefore when screwed into the 3.2 mm 45 
diameter pilot holes, the screw threads have full radial 
engagement with the bone stimulant. When the screws are 
inserted into larger diameter pilot holes, there is less radial 
thread engagement.
The screws were progressively inserted into the bone 50 
stimulant while measuring the required insertion torque. 
These measurements were accomplished by placing a force 
scale at the end of a hex wrench of the appropriate size for the 
bone screws. The maximum force required to turn the screws 
at various depths of engagement were recorded. Each force 55 
was multiplied by the perpendicular distance from the axis of 
the screw to the line of action of the force scale to obtain the 
insertion torque.
Torque measurements were made over 3 insertion depth 
regions of the screws. These regions were the ‘ 1st third” with 60 
2-3 complete threads engaged into the bone stimulant mea­
sured from the screw tip, and subsequently the “2”d third’ with 
4-6 total threads engaged, and the V d third” with 7-9 total 
threads engaged. The screws used (45 mm total length) had a 
total of approximately 11 complete threads. Each torque data 65 
point was calculated from 12 measurements for each “inser­
tion third”.
Insertion torque measurements were graphed and a bare 
screw was used as a control for comparison (FIG. 25). Inser­
tion torque was compared between the bare control screw and 
a nano tube-covered screw with a 3.2 mm diameter pilot hole 
with full radial thread engagement (FIG. 26). The nanotube- 
covered screws exhibited a lower insertion torque require­
ment, perhaps because of the lower mechanical stiffness of 
the surface. Without being bound to a particular theory, it has 
been hypothesized that this lower mechanical stiffness is 
partially responsible for increased cell growth and adhesion. 
Nanotube Survivability
Bone screws were inserted into and removed from bone 
stimulant with a 5.0 mm diameter pilot hole and then inserted 
into and removed from bone stimulant with a 3.2 mm diam­
eter hole. After undergoing these procedures, the bone screws 
were inspected in the SEM. Deposition of polyurethane on 
top of the bone screw was observed as a result of tapping the 
threaded hole in the bone stimulant. The polyurethane layer 
had openings through which intact nanotubes were observed 
(FIG. 27). To remove this contamination layer, the nanotube 
covered screws were heated at 350° C. for 30 minutes to 
vaporize the polyurethane. The screw was then sonicated in 
water to remove any remaining debris. After this aggressive 
treatment, the screw was re-examined in the SEM confirming 
that the nanotubes had remained intact (FIG. 28).
Thus, using graphite electrodes, nanotubular structures 
were fabricated into Ti6A14V ELI surgical orthopedic can­
cellous and cortical bone screws. The nanotubes on the bone 
screws survived multiple insertion and removal cycles in an 
accepted bone stimulant material.
Example 6
Deposition of Silver on T i02 Nanotube Surfaces
Nanotubes were fabricated onto and/or into the surface of 
Ti6A14V titanium alloy by anodization using an AgF electro­
lyte. T i02 nanotube surfaces made in this manner were stud­
ied for the purpose of depositing silver on titanium surfaces.
The fabrication process used an etching system involving a 
Ti anode, a counter electrode, an electrolyte, and a DC power 
source. The substrates for nanotube etching were flat, 2 cmx3 
cm area and 0.25 mm thickness, and polished with 0.06 mm 
colloidal S i02. Prior to nanotube etching, the substrates were 
sequentially sonicated in acetone, isopropyl alcohol, and 
methanol, then rinsed with deionized water and dried in an N2 
stream. The experimental setup consisted of a two-electrode 
arrangement. Graphite was used as the counter electrode for 
the anodizations. The spacing between the substrates and the 
counter electrode was approximately 25 mm. Etching condi­
tions were 60 VDC and a time of 30 minutes. The anodization 
was carried out at room temperature. The electrolyte was a 
solution of AgF in 49 ml ethylene glycol and 1 ml deionized 
water (49 mL ethylene glycol, 1 mL water, and 0.9 grams of 
silver fluoride). The innocuous etching electrolyte (AgF and 
ethylene glycol rather than F1F) makes the process consider­
ably safer, cheaper, and easier to maintain by eliminating the 
need for costly specialized environmental containment and 
disposal safeguards. Additionally, it ensures that any residual 
chemical etchant that might cling to the product surface 
would be essentially benign. A constant 60 V DC was used for 
all experiments. After anodization, the samples were rinsed 
with deionized water and dried in a N2 stream.
Nanotubes were fabricated on titanium alloy Ti6A14V with 
the AgF-containing electrolyte (FIGS. 30A and 30B). The 
nanotubes were approximately 2 microns in length.
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The T i02 nanotube fabrication process was modified so 
that after anodization (etching conditions: 60 VDC; 30 min­
utes), electrode polarity was immediately reversed. Again, 
nanotubes on titanium alloy Ti6A14V were fabricated with 
AgF-containing electrolyte (FIG. 31). When the T i02 nano­
tube fabrication process included reversing the electrode 
polarity for 15 minutes after anodization, silver was deposited 
on the titanium substrate surface. X-ray elemental analysis 
indicated that silver was deposited over the titanium substrate 
surface, and that silver was the second most abundant element 
after titanium. The titanium alloy is 6% by weight aluminum 
and 4% by weight vanadium, and the silver content appeared 
to be greater than either of these two alloy constituents. Thus, 
T i02 nanotube surfaces comprising silver were generated.
Example 7
Varying the Relative Presence of Silver in Nanotubes
The presence of silver in or on the nanotube surface can 
confer anti-bacterial properties of the surface. However, the 
amount of silver in or on the surface will impact those anti­
bacterial properties. For example, too low of a silver content 
has no adverse effect on bacteria whereas an overabundance 
of silver, while it can act as an anti-bacterial agent, can dam­
age normal tissue cells. The type of bacteria that are targeted 
and the bacteria’s resiliency will dictate an acceptable range 
of silver presence. It is therefore important to be able to adjust 
the silver presence during the single process step of creating 
silver-bearing titanium nanotubes.
Experiments were conducted to demonstrate this capabil­
ity according to embodiments of the invention. As discussed 
above, a nanotube-etching electrolyte is prepared by dissolv­
ing a given amount of silver fluoride in 2 mL of deionized 
water and 98 mL of ethylene glycol to produce a total of 100 
mL of etching electrolyte. In this Example, the mass of silver 
fluoride added to electrolyte was varied over a wide range, 
namely 0.1 grams, 1.1 grams, and 2.25 grams per 100 mL of 
electrolyte. Nanotubes were formed using 60 volts DC for a 
total duration of 20 minutes. The relative presence of silver, 
on both an atomic percent presence and a weight percent 
presence was measured by energy-dispersive X-ray spectros­
copy. The results are shown in FIG. 32.
As shown in FIG. 32, as the mass of silver fluoride present 
in the same volume of electrolyte increases, the presence of 
silver in the nanotube-covered sample surface rapidly 
increases, such as a seven-fold increase in the percent pres­
ence of silver atoms (diamonds, lower trace) and a five-fold 
increase in the weight of silver present (squares, upper trace).
The results disclosed herein demonstrate the capability to 
control the presence of silver which ends up in nanotubes 
following etching, which can in turn be used to affect a 
particular or several bacteria when lethal silver levels are 
known for those bacteria. In various embodiments, the 
amount of silver that is present during etching, which influ­
ences the amount of silver that is associated with the modified 
surface, may be varied in a range from 0.001 to 4 grams per 
100 mL of electrolyte solution, including amounts of 0.01 
grams, 0.5 grams, 1.0 grams, 1.5 grams, 2.0 grams, 3.0 grams, 
and 3.5 grams per 100 mL.
In other embodiments, the relative amount of silver in the 
final nanotube surface can be varied by varying the etching 
parameters that control the size of the nano tubes. Larger and 
longer nanotubes with more surface area will contain more 
silver. These etching variables include: (1) etch time, a longer 
etch time results in longer nanotubes and more open volume 
among the nanotubes (as previously shown) providing more
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surface onto/into which silver will be incorporated; and (2) 
etch voltage, a higher etching voltage results in longer nano­
tubes and more open volume among the nanotubes (as previ­
ously shown) providing more surface onto or into which 
silver will be incorporated.
Other Embodiments
From the foregoing description, it will be apparent that 
variations and modifications may be made to the invention 
described herein to adopt it to various usages and conditions. 
Such embodiments are also within the scope of the following 
claims.
The recitation of a listing of elements in any definition of a 
variable herein includes definitions of that variable as any 
single element or combination (or subcombination) of listed 
elements. The recitation of an embodiment herein includes 
that embodiment as any single embodiment or in combination 
with any other embodiments or portions thereof.
All patents and publications mentioned in this specification 
are herein incorporated by reference to the same extent as if 
each independent patent and publication was specifically and 
individually indicated to be incorporated by reference.
What is claimed is:
1. A method for modifying a surface by generating nano­
tubes at one or more selected sites on the surface, the surface 
comprising a first metal, the method comprising:
positioning at least one cathode and at least one anode 
relative to the surface in an electrolyte solution compris­
ing a fluoride salt of a second metal; and
applying a voltage between the at least one anode and the at 
least one cathode sufficient to generate nanotubes at one 
or more selected sites on the surface by removing a 
portion of the first metal from the surface by etching, and 
to inhibit nanotube formation at one or more of the other 
selected sites, wherein the nanotubes comprise the first 
metal and the second metal;
wherein the electrolyte solution comprises AgF or CaF2.
2. The method of claim 1, further comprising applying a 
voltage of reverse polarity to the at least one cathode and the 
at least one anode sufficient to deposit the second metal onto 
the surface.
3. The method of claim 1, wherein the first metal comprises 
titanium.
4. The method of claim 3, wherein the second metal com­
prises silver.
5. The method of claim 4, further comprising varying a 
level of silver in the electrolyte solution to vary an amount of 
silver associated with the surface.
6. The method of claim 5, wherein varying a level of silver 
in the electrolyte solution comprises adjusting a level of silver 
in a range from 0.1 to 2.25 grams per 100 mL of electrolyte 
solution.
7. The method of claim 6, wherein the electrolyte solution 
comprises ethylene glycol and water.
8. The method of claim 1, wherein the at least one cathode 
and the at least one anode comprise graphite.
9. The method of claim 1, wherein the second metal 
reduces the propensity of the surface to support bacterial cell 
growth.
10. The method of claim 1, wherein the voltage is approxi­
mately 60 VDC.
11. The method of claim 1, wherein the surface comprises 
titanium.
12. The method of claim 1, further comprising coating the 
surface with at least one of an anti-bacterial agent, a growth 
factor, and an anti-inflammatory agent.
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13. The method of claim 1, further comprising loading the 
nanotubes with an effective amount of a biologically active 
agent.
14. The method of claim 1, wherein the surface is present 
on a biomedical implant or medical device.
15. The method of claim 1, wherein the surface is present 
on a biomedical implant which is selected from the group 
consisting of a dental implant, a cardiovascular implant, a 
neurological implant, a neurovascular implant, a gastrointes­
tinal implant, a muscular implant, an orthopedic implant, a 
cochlear implant, and an ocular implant.
16. The method of claim 1, wherein the surface is present 
on an orthopedic implant which is selected from the group 
consisting of joint implants, spinal implants, screws, pins, 
rods, and plates.
17. A method for modifying a surface by generating nano­
tubes at one or more selected sites on the surface, the surface 
comprising a first metal, the method comprising:
positioning at least one cathode and at least one anode 
relative to the surface in an electrolyte solution compris­
ing a fluoride salt of a second metal; and
applying a voltage between the at least one anode and the at 
least one cathode sufficient to generate nanotubes at one 
or more selected sites on the surface by removing a 
portion of the first metal from the surface by etching, and 
to inhibit nanotube formation at one or more of the other 
selected sites, wherein the nanotubes comprise the first 
metal and the second metal; and
applying a voltage of reverse polarity to the at least one 
cathode and the at least one anode sufficient to deposit 
the second metal onto the surface.
18. A method for modifying a surface by generating nano­
tubes at one or more selected sites on the surface, the surface 
comprising a first metal, the method comprising:
positioning at least one cathode and at least one anode 
relative to the surface in an electrolyte solution compris­
ing a fluoride salt of a second metal; and
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applying a voltage between the at least one anode and the at 
least one cathode sufficient to generate nanotubes at one 
or more selected sites on the surface by removing a 
portion of the first metal from the surface by etching, and 
to inhibit nanotube formation at one or more of the other 
selected sites, wherein the nanotubes comprise the first 
metal and the second metal;
wherein the first metal comprises titanium, and the second 
metal comprises silver.
19. The method of claim 18, further comprising varying a 
level of silver in the electrolyte solution to vary an amount of 
silver associated with the surface.
20. The method of claim 19, wherein varying a level of 
silver in the electrolyte solution comprises adjusting a level of 
silver in a range from 0.1 to 2.25 grams per 100 mL of 
electrolyte solution.
21. The method of claim 20, wherein the electrolyte solu­
tion comprises ethylene glycol and water.
22. A method for modifying a surface by generating nano­
tubes at one or more selected sites on the surface, the surface 
comprising a first metal, the method comprising:
positioning at least one cathode and at least one anode 
relative to the surface in an electrolyte solution compris­
ing a fluoride salt of a second metal; and
applying a voltage between the at least one anode and the at 
least one cathode sufficient to generate nanotubes at one 
or more selected sites on the surface by removing a 
portion of the first metal from the surface by etching, and 
to inhibit nanotube formation at one or more of the other 
selected sites, wherein the nanotubes comprise the first 
metal and the second metal;
wherein the at least one cathode and the at least one anode 
comprise graphite.
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